Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 1 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 
 
 
Clinical  Investigation  Plan  
Clinical  Investigation  Plan/Study  Title  Reveal  LINQTM for Chronic  Obstructive  Pulmonary  
Disease  (COPD)  
Clinical  Investigation  Plan  Identifier  MDT19019  
Study  Product  Name  [CONTACT_600562]  (ICM)  
System  
Sponsor/Local  Sponsor  Sponsor:  
Medtronic,  Inc US 
[ADDRESS_795280] NE 
Mounds  View,  MN U.S.A.  [ZIP_CODE] 
Phone: 1 -[PHONE_10901]  
Document  Version  5.[ADDRESS_795281]  Information  ................................ ................................ ................................ ..... 7 
2. Glossary  ................................ ................................ ................................ ............................... 7 
3. Synopsis  ................................ ................................ ................................ ...........................  10 
4. Introduction  ................................ ................................ ................................ .....................  14 
4.1 Background  ................................ ................................ ................................ ............................  14 
4.2 Purpose  ................................ ................................ ................................ ................................ . 15 
5. Objectives  and/or  Endpoints  ................................ ................................ ............................  16 
5.1 Objectives  ................................ ................................ ................................ ..............................  16 
5.1.1 Primary  Objective(s)  ................................ ................................ ................................ ............  [ADDRESS_795282]  Description  ................................ ................................ ................................ ..........  19 
7.1 General  ................................ ................................ ................................ ................................ . 19 
7.1.1 Reveal  LINQTM Insertable  Cardiac  Monitor  (ICM)  ................................ ................................  20 
7.1.2 Incision  Tool ................................ ................................ ................................ .........................  21 
7.1.3 Insertion  Tool................................ ................................ ................................ .......................  21 
7.1.4 2090  Programmer  ................................ ................................ ................................ ...............  22 
7.1.5 Medtronic  Investigational  RAMware  ................................ ................................ ...................  22 
7.1.6 Patient  Assistant  ................................ ................................ ................................ ..................  23 
7.1.7 MyCareLink  ® Home  Monitor  ................................ ................................ ..............................  [ADDRESS_795283] 220 Holter  Monitor  ................................ ................................ ................................ ........  24 
7.1.9 EMFIT  QS + CARETM Bed Monitor  ................................ ................................ ........................  [ADDRESS_795284]  Accountability  ................................ ................................ ................................ .............  28 
7.11.1  CareLink  Programmer  ................................ ................................ ................................ ..........  29 
7.11.2  Reveal  LINQ  ICM ................................ ................................ ................................ ..................  29 
7.11.3  Patient  Assistant  ................................ ................................ ................................ ..................  29 
7.11.4  Holter  DR220  ................................ ................................ ................................ .......................  29 
7.11.5  EMFIT  QS+CARETM bed monitor  ................................ ................................ ..........................  29 
8. Study  Site Requirements  ................................ ................................ ................................ .. 29 
8.1 Investigator/Investigation  Site Selection  ................................ ................................ ...................  [ADDRESS_795285]  Consent  ................................ ................................ ................................ .....................  35 
10.6 Enrollment  ................................ ................................ ................................ .............................  36 
10.7 Baseline  ................................ ................................ ................................ ................................ . 36 
10.8 Implant  ................................ ................................ ................................ ................................ . 37 
10.8.1  Device  Programming  Requirements  ................................ ................................ ....................  38 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 4 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 10.9 EMFIT -QS+CARE ™ Bed Monitor  ................................ ................................ ..............................  [ADDRESS_795286]  Diary ................................ ................................ ................................ ....... 38 
10.11  Bi-Weekly  CareLink  Transmissions  ................................ ................................ ....................  39 
10.12  Scheduled  Follow -up Visits ................................ ................................ ...............................  39 
10.12.1  Phone  Follow -up Visit  (every  3 months)  ................................ ................................ .........  39 
10.12.2  In-Office  Follow -up Visit  (optional) ................................ ................................ ..................  [ADDRESS_795287]  Chooses  to Exit (i.e. Revokes  Consent)  ................................ ...............................  [ADDRESS_795288]  ................................ ................................ ......................  45 
10.23.6  Conditional  Disengagement  ................................ ................................ ............................  45 
11. Risks  and Benefits  ................................ ................................ ................................ .........  46 
11.1 Potential  Risks ................................ ................................ ................................ ........................  46 
11.2 Risk Minimization  ................................ ................................ ................................ ....................  47 
11.3 Potential  Benefits  ................................ ................................ ................................ ...................  50 
11.4 Risk-Benefit  Rationale  ................................ ................................ ................................ .............  51 
12. Adverse  Events  and Device  Deficiencies  ................................ ................................ ........ 51 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 5 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 12.1 Adverse  Events  ................................ ................................ ................................ ......................  51 
12.2 Device  Deficiency  ................................ ................................ ................................ ...................  52 
12.3 Processing  Updates  and Resolution  ................................ ................................ ..........................  52 
12.4 Definitions/Classifications  ................................ ................................ ................................ ........  [ADDRESS_795289]  Complaint  Reporting  ................................ ................................ ................................ ... 62 
13. Data  Review  Committees  ................................ ................................ ..............................  62 
13.1 Event  Adjudication  Committee  ................................ ................................ ................................ . 62 
13.2 CRO ................................ ................................ ................................ ................................ ...... 63 
14. Statistical  Design  and Methods  ................................ ................................ .....................  63 
14.1 General  Aspects  of Analysis  ................................ ................................ ................................ ..... 63 
14.2 Analysis  Execution  ................................ ................................ ................................ ..................  64 
14.3 Primary  Objective  ................................ ................................ ................................ ...................  64 
14.3.1  Hypothesis  ................................ ................................ ................................ ...........................  64 
14.3.2  Endpoint  Definition  ................................ ................................ ................................ .............  64 
14.3.3  Analysis  Methods  ................................ ................................ ................................ ................  64 
14.3.4  Determination  of Subjects/Data  for Analysis  ................................ ................................ ...... 64 
14.4 Sample  Size Determination  ................................ ................................ ................................ ...... 65 
14.5 Minimization  of Bias ................................ ................................ ................................ ................  65 
14.6 Missing  data ................................ ................................ ................................ ...........................  65 
14.7 Additional  Considerations  Due to COVID -19 ................................ ................................ ..............  66 
15. Ethics  ................................ ................................ ................................ ............................  66 
15.1 Statement(s)  of Compliance  ................................ ................................ ................................ .... [ADDRESS_795290]  Access  to Source  Data/Documents  ................................ ................................ .................  [ADDRESS_795291]  Retention  ................................ ................................ ................................ ....................  69 
16.7.1  Investigator  Records  ................................ ................................ ................................ ............  69 
16.7.2  Sponsor  Records  ................................ ................................ ................................ ..................  70 
16.8 Reporting  Requirements  ................................ ................................ ................................ ..........  70 
16.8.1  Investigator  Reports  ................................ ................................ ................................ ............  70 
16.8.2  Sponsor  Reports  ................................ ................................ ................................ ..................  71 
16.9 Publication  and Use of Information  ................................ ................................ ..........................  72 
16.9.1  Publication  Committee  ................................ ................................ ................................ ........  72 
16.9.2  Management  of Primary,  and Ancillary  Publications ................................ ...........................  73 
16.9.3  Criteria  for Determining  Authorship  ................................ ................................ ....................  73 
16.9.4  Transparency  ................................ ................................ ................................ .......................  74 
16.10  Suspension  or Early Termination  ................................ ................................ ......................  74 
16.10.1  Planned  Study  Closure  ................................ ................................ ................................ ..... 74 
16.10.2  Early  Termination  or Suspension  ................................ ................................ .....................  74 
16.10.3  Procedures  for Termination  or Suspension  ................................ ................................ ..... 75 
17. References  ................................ ................................ ................................ ....................  76 
18. Appendices  ................................ ................................ ................................ ....................  77 
18.1 Informed  Consent  Template(s)  ................................ ................................ ................................  77 
18.2 Data Collection  Elements  (Electronic  Case Report  Forms)  ................................ ..........................  [ADDRESS_795292]  information  will be sent  to the centers  as needed . 
Table  1: Sponsor  Contact  [CONTACT_239013]/US  contact  
[CONTACT_600503] X
XXXXXXXXXXXXXXXXXXXX  
XXXXXXXXXXXXXXXXXXXXXXX  
Monitoring  Contacts  
Worldwide  monitoring  leader/US  contact  
[CONTACT_600504]  
 
 
2.  Glossary   
 
Term  Definition  
ADE Adverse  device  effect  
ADHF  Acute  Decompensated  Heart  Failure  
AE Adverse  event  
AF Atrial  Fibrillation  
ALLEVIATE -HF RAMware  Investigational  software  downloaded  to the LINQTM 
TruRhythm  device  in study  subjects  
BCSS  Breathlessness,  Cough,  and Sputum  Scale  
BNP Brain  natriuretic  peptide  
CFR Code  of Federal  Regulations  
CIP Clinical  Investigation  Plan 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795293]  Mobile  cardiac  telemetry  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MiD Monitoring  in Dialysis  
NSR Non -significant  Risk 
NT-proBNP  N-terminal  brain  natriuretic  peptide  
PRN ‘pro re nata’  – as needed  
RDC Remote  data  capture  
RR Respi[INVESTIGATOR_600467]  5.0, 
1-DEC-[ADDRESS_795294]. George’s  Respi[INVESTIGATOR_600468]  
 
3.  Synopsis   
 
Title  Reveal  LINQTM for COPD  
Clinical  Study  Type  Prospective,  non-randomized,  multi -center,  observational,  pre-market  clinical  study.  
Product  Name  [CONTACT_600563]  (ICM)  System  with  either  LINQ  HF or ALLEVIATE -HF 
investigational  RAMware  download  
Sponsor / 
Local  Sponsors  Sponsor:  
Medtronic,  Inc US 
[ADDRESS_795295] NE 
Mounds  View,  MN U.S.A.  [ZIP_CODE] 
Phone: 1 -[PHONE_10901]  
Indication  under 
investigation  The study  is utilizing  investigational  RAMware,  either  LINQ  HF OR ALLEVIATE -HF, that will be 
downloaded onto the subject’s market -released Medtronic Reveal LINQ ICM. The 
investigational RAMware enables the hardware to record and store additional sensor data.  
 
The market -released  indication  is provided  below:  
 
The Reveal  LINQ  ICM is an insertable  automatically  activated  and patient  activated  monitoring 
system that records subcutaneous ECG and is indicated in the following cases:  
• Patients  with  clinical  syndromes  or situations  at increased  risk of 
cardiac arrhythmias  
• Patients  who  experience  transient  symptoms  such  as dizziness, 
palpi[INVESTIGATOR_332], syncope, and chest pain that may suggest a cardiac 
arrhythmia  
The device  has not been  tested  specifically  for pediatric  use. 
Investigation  
Purpose  The purpose  of the LINQ ™ for COPD  study  is to characterize  Reveal  LINQ ™ derived  data  from  
patients  with  COPD  by [CONTACT_600505] ™ derived  data  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795296]  Status   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The LINQ ™ device and the 2090 programmer are market -released, but once the 
investigational  Software  or RAMware  is downloaded  into the devices,  they  are considered 
investigational.  
**Subjects  will receive  the most  current  approved  version  of the investigational  RAMware  at 
the time of their device insertion.  
Study Objective  The study  objective  is to characterize  Reveal  LINQ ™ derived  data  from  patients  with  COPD  by 
[CONTACT_600506] ™ derived data with COPD events 
collected during the study.  
Study  Design  The Reveal  LINQ ™ for COPD  study  is a Non-significant  Risk IDE, observational,  non- 
randomized,  multi -center,  clinical  study.  The study  is expected  to be conducted  at up to 10 Model 
Number   
Component   
Manufacturer  Investigational  or 
Market -released  
LNQ11  Reveal  LINQ ™ Insertable  Cardiac 
Monitor  Medtronic  Market -Released*  
LNQ11  Incision  Tool Medtronic  Market -Released  
LNQ11  Insertion  Tool Medtronic  Market -Released  
SW026  2090  Programmer  Medtronic  Market -Released*  
Not 
Applicable  LINQ  HF RAMware,  Version  1.1 and 
subsequent versions as they are 
released**  Medtronic  Investigational  
Not 
Applicable  LINQ HF Software, Rev 1.1 and 
subsequent  versions  as they  are 
released  Medtronic  Investigational  
Not 
Applicable  ALLEVIATE -HF RAMware,  Version  
1.32  and subsequent  versions  as 
they are released**  Medtronic  Investigational  
ALVT22  ALLEVIATE -HF Software, Rev 1.1 
and subsequent  versions  as they 
are released  Medtronic  Investigational  
PA96000  Patient  Assistant  Medtronic  Market -Released  
[ZIP_CODE]  MyCareLink®  Home  Monitor  Medtronic  Market -Released  
DR220  Holter  NorthEast 
Monitoring,  Inc. Market -Released  
IP-9260  QS+CARE ™ Bed Monitor  EMFIT  Market -Released  
 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 12 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 centers  in the United  States  and up to 100 subjects  will be enrolled,  with  no more than  20 
subjects enrolled per site.  
All enrolled  subjects  will be  implanted  with a  Reveal  LINQTM Insertable Cardiac  Monitor  (ICM) 
with either the investigational LINQ HF or ALLEVIATE -HF RAMware download, and will be 
followed until the last subjects’ 6 -month follow -up visit is completed or until official study 
closure, defined as when Medtronic and/or regulatory requirements have been satisfied per 
the Clinical Investigation Plan and/or by a decision by [CONTACT_131488], 
whichever occurs first.  Accordingly, the expected total study duration is approximately [ADDRESS_795297] 6 months of 
follow -up with  1 month  between  enrollment  and insertion.  All LINQTM system  and procedure - 
related  adverse events (AEs), all serious  adverse  events (SAEs),  all Pulmonary  related  AEs and 
all Cardiovascular related AEs will be collected throughout the study duration of a subject’s 
participation in the study, beginning at the time of informed consent.  
Sample  Size The study  may  enroll  approximately  100 subjects  
Inclusion/Exclusion 
Criteria  Inclusion  Criteria  
• Patient  is ≥ 45 years  old 
• Patient  (or patient’s  legally  authorized  representative)  is willing  and able  to provide 
written informed consent  
• Patient  is willing  and able  to comply  with  the protocol,  including  follow -up visits,  diary 
submissions and CareLink transmissions  
• FEV 1 (post  bronchodilator)  ≤ 70%  of predicted  
• Current  or former  smoker  with  lifetime  cigarette  consumption  of > 10 pack -years  
• One COPD  exacerbation  in the previous  12 months  requiring  hospi[INVESTIGATOR_059], urgent care 
or emergency  department  visit for respi[INVESTIGATOR_600469] 12 months requiring antibiotics and/or corticosteroids for respi[INVESTIGATOR_037]  
• The patient’s  medical  records  must  be accessible  by [CONTACT_600507] -up 
period  
 
Exclusion  Criteria  
• Less  than  30 days  from  diagnosis  of a COPD  exacerbation  as defined  as taking  antibiotics 
and/or corticosteroids for respi[INVESTIGATOR_1856], hospi[INVESTIGATOR_059], urgent care or 
emergency department visit for respi[INVESTIGATOR_4375]. *  
• Less  than  30 days  from  diagnosis  of a HF event  as defined  as any cardiovascular -related 
(including hypervolemia) Health Care Utilizations (HCUs) for any one of the following 
events: Admission with primary diagnosis of HF or Intravenous HF therapy (e.g. IV 
diuretics/vasodilators) or ultrafiltration at any one of the foll owing settings: Admission 
with secondary/tertiary diagnosis of HF, Emergency Department, Ambulance, 
Observation Unit, Urgent Care, or HF/Cardiology Clinic  
• Active  respi[INVESTIGATOR_600470]/or  corticosteroids  
• Class  IV heart  failure  
• Clinical  diagnosis  of unstable  angina,  bronchiectasis,  or cystic  fibrosis  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 13 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 • Any concomitant  condition  that might  endanger  the patient  through  participation  in the 
study or interfere with study procedures, as assessed by [CONTACT_093]  
• Patient  is pregnant  (all females  of child -bearing  potential  must  have  a negative 
pregnancy test within 1 week of enrollment)  
• Patient  is enrolled  in another  study  that could  confound  the results  of this study,  without 
documented pre -approval from a Medtronic study manager  
• Patient  has an existing  or planned  implantation  of Medtronic  IPG, ICD, CRT-D or CRT-P 
device in the near future  
• Patient  has an existing  and active  insertable  cardiac  monitor,  regardless  of 
manufacturer.# 
• Concurrent  disease  with  life expectancy  less than  1 year  
* This exclusion  criterion  has been  removed  as documented  in the Intended  CIP deviation 
dated [ADDRESS_795298]-2021  
# This exclusion  criterion  has been  updated  to “Patient  has an active  non-Medtronic 
insertable cardiac monitor” in the Intended CIP deviation dated [ADDRESS_795299]-2021  
Study  Procedures 
and Assessments  When  a patient  or Legally  authorized  representative  (LAR)  and the principal  investigator  [INVESTIGATOR_600471], and dated the Patient Informed Consent Form, the patient is considered a subject 
enrolled in the study. Following consent, a baseline assessment will be completed, and 
subjects will undergo a Reveal LINQTM device insertion including either the LINQ HF or 
ALLEVIATE -HF investigational RAMware download within [ADDRESS_795300]  device  insertion  (visits  may  also be conducted  in-person  if desired).  The optional 
in-office follow -up visit however can be conducted at any  time during study participation, 
except within [ADDRESS_795301] insertion of the device. All enrolled subjects will be followed until 
study closure. Data collection and procedures are summarized below:  
 
Baseline:  Informed consent, inclusion/exclusion assessment, medical history, subject 
demographics, SGRQ, Baseline Measurements, Medication Assessment, subject diary 
enrollment,  Labs,  Spi[INVESTIGATOR_487383]  (pre and post  bronchodilator),  adverse  events,  study 
deviations  
 
LINQ  Insertion  Visit:  LINQTM insertion,  LINQ  HF OR ALLEVIATE -HF RAMware  download,  device 
interrogation (save to media via USB), system and procedure information, adverse events, 
device deficiencies, study deviations  
 
Subject  Diary  (weekly) : BCSS  Questionnaire,  PRN  medication  assessment  
Scheduled  Phone  Follow -up Visits  (every  3 months):  Medication  assessment,  adverse  events, 
device deficiencies, study deviations  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 14 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
  
Scheduled In -office Follow -up Visit (optional):  Baseline Measurements, medication 
assessment, device interrogation (save to media via USB) (pre and post visit procedures), 
spi[INVESTIGATOR_600472],  patient  assistant  activity,  Chest  x-ray, adverse  events,  device 
deficiencies, study deviations  
 
Study  Exit Visit:  Reason  for exit,  removal  of LINQ  HF or ALLEVIATE -HF RAMware  from  LINQTM 
device, device interrogation (save to media via USB), opting out of the subject diary, SGRQ, 
Medication assessment, labs, adverse events, device deficiencies, study deviations  
Additionally,  up to [ADDRESS_795302] deaths will be collected.  
Safety  Assessments  All LINQTM system and procedure -related adverse events (AEs), all serious adverse events 
(SAEs), all Pulmonary related AEs and all Cardiovascular related AEs will be collected 
throughout the study duration of a subject’s participation in the study, beginning at the time 
of informed  consent.  An Event  Adjudication  Committee  (EAC)  will conduct  a medical  review  of 
all adverse events  classified  by [CONTACT_600508]  a fatal  outcome.  The EAC will consist  of non-Medtronic  employed  physicians  that are not 
participating  investigators  for the study.  
Statistics  Since the study will be exploratory in nature and the study objectives are descriptive, no 
clinical  endpoints  will be developed.  LINQ ™ derived  data  will be summarized  using  descriptive 
statistics.  Their relationship to COPD events (per EAC adjudication) will be evaluated by 
[CONTACT_600509].  
 
 
4.  Introduction   
4.[ADDRESS_795303] their cardiac rhythm.  
The current  indications  are: 
US Indications:  
• Patients  with  clinical  syndromes  or situations  at increased  risk of cardiac  arrhythmias.  
• Patients  who  experience  transient  symptoms  such  as dizziness,  palpi[INVESTIGATOR_332],  syncope  and chest 
pain that may suggest a cardiac arrhythmia.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 15 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Chronic Obstructive Pulmonary Disease (COPD) is progressive and currently incurable and refers to a 
collection  of diseases that lead to the key feature of irreversible airflow limitation and breathing related 
problems.  It is characterized  by [CONTACT_600510],  small  airway  remodeling,  a progressive  decline 
in FEV1 (Forced Expi[INVESTIGATOR_117067]), decreased lung emptying, and static and dynamic hyperinflation1. 
Particulate  exposure  can lead  to mucosal  and glandular  inflammation,  increased  mucous  discharge  and 
epi[INVESTIGATOR_126308], and altered tissue repair in small conducting airways1. COPD is the third leading 
cause of death worldwide, with an estimated prevalence of 175 million1. Of those with COPD, 46% 
experienced at least one exacerbation within the previous year and 19% needed hospi[INVESTIGATOR_059]2. 
Approximately  11%  of those  admitted  for exacerbation  die within  90 days,  with  half occurring  during  the 
hospi[INVESTIGATOR_059]1. 35% of those admitted for exacerbation are readmitted within 90 days1. The financial 
burden of COPD is also evident, in that over $32 billion was spent for COPD care in the [LOCATION_002] in 
2010 and it is expected to be close to $50 billion in [ZIP_CODE]. More than 70% of the spending is related to 
hospi[INVESTIGATOR_600473]. Most COPD exacerbations are caused 
by [CONTACT_80601], with other major triggers including outdoor and indoor particulate air pollution and  
weather2. Confounding these metrics is the fact that there is much overlap in COPD with other 
concurrent disease.  Approximately 1/3 of COPD patients die of cardiovascular disease and 1/[ADDRESS_795304] airflow limitation1. 
Reducing  healthcare  utilization  associated  with  COPD  patient  management  (i.e. short -term  readmission 
and chronic disease management) is a critically important unmet need for patients, caregivers, and 
hospi[INVESTIGATOR_600].  Early detection, prevention, and treatment of COPD exacerbation would aim to reduce this 
high morbidity and cost.  
 
 
4.[ADDRESS_795305] an exacerbation for COPD using the 
traditional evaluation measures such as physical signs and symptoms is limited.  Medical interventional 
methods currently may not identify patients early enough to prevent an exacerbation.  To help reduce 
these exacerbations and improve disease management, sensors in a minimally invasive device can be 
used  to identify  factors  that are associated  with  exacerbations.  Thus,  a solution  to continuously  monitor 
COPD pati ents at risk for acute exacerbations (GOLD stage C/D) in an ambulatory fashion to predict 
symptom worsening and provide timely remote intervention to prevent hospi[INVESTIGATOR_600474].  Using sensors in a minimally invasive device like LINQTM to sense, predict 
and prevent COPD hospi[INVESTIGATOR_600475].  As a first step, the LINQ - 
COPD study aims to collect sensor data to characterize the changes in these sensor data prior to COPD 
hospi[INVESTIGATOR_600476] a prediction algorithm that can identify when patients are risk 
and may benefit from a  remote intervention.  
Prior  studies  have  shown  implantable  device -measured  diagnostics  like intra -thoracic  impedance,[ADDRESS_795306] 
physiological changes associated with COPD.  
The use of implantable device features such as the OptiVol ™ impedance algorithm is clinically useful in 
monitoring  thoracic  fluid  status  for pacemaker  or ICDs  and may  be measured  in the subcutaneous  space. 
8 The Monitoring in Dialysis (MiD) study was conducted in renal failure patients implanted with a Reveal 
LINQ ™ insertable cardiac monitor. The results indicated impedance trends upwards with fluid removal 
during dialysis sessions and  downwards between dialysis sessions. Therefore,  the preliminary data show 
that continuous  impedance  monitoring  has a direct  inverse  relationship  to patient  thoracic  fluid  status  in 
both a detailed analysis and long -term trending analysis.9 
Respi[INVESTIGATOR_600477].  Respi[INVESTIGATOR_600478].10,11 The NOTICE - 
HF study, patient ambulatory respi[INVESTIGATOR_1487] (RR) was monitored using an ICD or CRT defibrillator.[ADDRESS_795307] amplitude variations.  
The LINQ ™ for COPD  study  will collect  and characterize  Reveal  LINQ ™ derived  data  from  patients  with 
COPD by [CONTACT_600506] ™ derived data with COPD exacerbation 
events. The  study  will also  collect information  regarding  COPD related  clinical  events during  the same 
period.  
 
5.  Objectives  and/or  Endpoints   
5.1 Objectives  
The study  objective  has been  defined  to characterize  the Reveal  LINQ ™ derived  data  in patients  with 
COPD related to COPD events.  
The study  objective  will be characterized,  and a final  study  report  will be completed  after  the final  study 
exit.  
5.1.1  Primary  Objective(s)  
• The primary objective is to characterize Reveal LINQ ™ derived data from patients with COPD by 
[CONTACT_600505] ™ derived  data  with  subsequent  COPD  events.  
 
COPD  event  is defined  as an adverse  event  where  the underlying  COPD  condition  exacerbates 
beyond normal day -to-day variations, where an increase in dyspnea, cough, and/or sputum  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 17 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 production  presents  with  acute  onset  and necessitates  supplementing  regular  COPD  medications 
with antibiotics for respi[INVESTIGATOR_600479]/or steroids.  
 
6.  Study  Design   
The LINQTM for COPD is a prospective, non -randomized, multi -center, observational, pre -market clinical 
study. The study may enroll up to [ADDRESS_795308] reaches their  6- 
month visit or until official study closure defined as when Medtronic and/or regulatory requirements 
have been satisfied per the Clinical Investigation Plan and/or by a decision by [CONTACT_600511], whichever occurs first. .  Accordingly, the expected total study duration is approximately [ADDRESS_795309] 6 months of follow -up 
with 1 month between enrollment and insertion. All Reveal LINQ ™ system and procedure -related 
adverse  events  will be collected  and reported  per the study  protocol.  In addition,  all SAEs,  all Respi[INVESTIGATOR_600480] (regardless of seriousness) and all Cardiovascular related AEs (regardless of seriousness) will 
be collected and reported per study protocol.  
Following consent, subjects will undergo a baseline assessment followed by [CONTACT_600512]. Following insertion, subjects will complete a weekly diary entry, which includes 
answering the BCSS Questionnaire and recording any PRN medications. Additionally, subjects will 
complete telephone follow -up visits every thre e months post device insertion (visits may also be 
conducted  in-person  if desired).  The optional  in-office  follow -up visit however  can be conducted  at any 
time  during  stud y participation,  except  within  [ADDRESS_795310]  insertion  of the device.  All enrolled  subjects 
will be followed until study closure. A study flowchart is shown in Figure 1.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 18 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Figure  1: Study  Flowchart  
 
 
 
6.[ADDRESS_795311]  reaches  their  6-month  visit or until  official  study 
closure defined as when  Medtronic and/or regulatory  requirements have been satisfied per the Clinical 
Investigation Plan (CIP) and/or by a decision by [CONTACT_600513] (i.e. Ethics 
Committee (EC) Regulatory Authority) whichever occurs first. The estimated total study duration is 
approximately [ADDRESS_795312] such data in relation to COPD exacerbations in a non -obtrusive 
manner.  The data collected will be used to develop methods for predicting and preventing COPD 
exacerbations,  and ultimately  to take  aim at the unmet  need  of reducing  healthcare  utilization  in COPD 
patient management.  
Safety will not be a primary focus of this study as 1) the study is only collecting observational data, 2) 
data collected will not be used to manage the treatment of subjects in the study, 3) data collection 
procedures  other  than  those  related  to the LINQTM are not outside  standard  of care  for COPD  patients 
and 4) the safety profile of LINQTM is already well known.[ADDRESS_795313]  information  is provided 
below.  
Table  2: Overall  Study  Principal  Investigator  [INVESTIGATOR_600481]  
 
7.  Product  Description   
7.1 General  
The Medtronic LINQTM ICM is an approved,  programmable device  that continuously monitors  a patient’s 
electrocardiogram (ECG) and other physiological parameters. The device records cardiac information in 
response  to automatically  detected  arrhythmias  and patient  activation.  The LINQTM device  is indicated  in 
the following:  
US Indications:  
• Patients  with  clinical  syndromes  or situations  at increased  risk of cardiac  arrhythmias.  
• Patients  who  experience  transient  symptoms  such  as dizziness,  palpi[INVESTIGATOR_332],  syncope  and chest 
pain that may suggest a cardiac arrhythmia.  
The study will be conducted using the components described in Table  below. All components of the 
LINQTM system  are manufactured  by [CONTACT_13735],  Inc. Instructions  for use of the devices  used  in this study 
are provided within their respective manuals.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 20 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Table  3: Study  Components  
 
Model 
Number   
Component   
Manufacturer  Investigational  or Market - 
released  
LNQ11  Reveal  LINQ ™ Insertable  Cardiac 
Monitor  Medtronic  Market -Released*  
LNQ11  Incision  Tool Medtronic  Market -Released  
LNQ11  Insertion  Tool Medtronic  Market -Released  
SW026  2090  Programmer  Medtronic  Market -Released*  
Not Applicable  LINQ  HF RAMware,  Version  1.1 and 
subsequent versions as they are 
released**  Medtronic  Investigational  
Not Applicable  LINQ HF Software, Rev 1.1 and 
subsequent  versions  as they  are 
released  Medtronic  Investigational  
Not Applicable  ALLEVIATE -HF RAMware,  Version  
1.32  and subsequent  versions  as 
they are released**  Medtronic  Investigational  
ALVT22  ALLEVIATE -HF Software, Rev 1.1 
and subsequent  versions  as they 
are released  Medtronic  Investigational  
PA96000  Patient  Assistant  Medtronic  Market -Released  
[ZIP_CODE]  MyCareLink®  Home  Monitor  Medtronic  Market -Released  
DR220  Holter  NorthEast  Monitoring,  Inc. Market -Released  
IP-9260  QS+CARE ™ Bed Monitor  EMFIT  Market -Released  
*The  LINQTM device  and the 2090 programmer  are market -released,  but once  the investigational  LINQ  HF OR ALLEVIATE -HF 
programmer application and the investigational RAMware are downloaded onto the devices, they are considered 
investigational.  
** Subjects  will receive  the most current  approved  version  of the investigational  RAMware  at the time  of their  device  insertion. 
In the case that a new RAMware version is released during the course of the study, subjects previously receiving an older 
version of the RAMware will receive an upgrade to the new version.  
 
Descriptions  of each  component  of the system  are provided  in the sections  below.  
7.1.1  Reveal  LINQTM Insertable  Cardiac  Monitor  (ICM)  
The Reveal LINQTM ICM is  a small, leadless  device that is inserted  under the  skin, in  the chest. A specific 
recommended location is provided within the product manual. The device uses two electrodes on the 
body  of the device  to continuously  monitor  the patient’s  subcutaneous  ECG.  The device  can store  up to 
30 min of ECG recordings  from  the patient -activated  epi[INVESTIGATOR_600482] 27 min of ECG recordings  from 
the automatically detected arrhythmias. Documentation of epi[INVESTIGATOR_321104].  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 21 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 
Figure  2: Reveal  LINQTM ICM 
 
 
7.1.2  Incision  Tool 
The Incision  Tool  is designed  to create an  incision  of repeatable  width  and depth  with  a single  motion.  It 
is composed of a blade, designed to make a repeatable incision, and handle, designed to ergonomically 
fit the clinician’s hand. The Reveal LINQ ™ Incision Tool is intended to make the incision simple and 
repeatable.  
 
Figure  3: Incision  Tool 
 
 
7.1.[ADDRESS_795314] with the 
surrounding  tissue  in a highly  repeatable  manner  and is composed  of two parts:  a handle  and a plunger. 
The Handle is composed of a “channel” section, used to hold the device and guide it during insertion, 
and a “Tunneler,” used to bluntly dissect an implant path for the device to travel down while being 
inserted. The plunger part is used to push th e device out of the handle, through the incision, and along 
the insertion path created by [CONTACT_600514].  
The Reveal  LINQ ™ device  will be loaded  in the Insertion  Tool  and sterilely  packaged  with  the Incision 
Tool. The Reveal LINQ ™ Insertion Tool is used to create an implant path in the body and deliver the 
Reveal LINQ ™ into the desired location.  

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 22 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Figure  4: Insertion  Tool 
 
 
 
7.1.4  2090 Programmer  
The Medtronic  CareLink®  Programmer  is used  to program  the Reveal  LINQ ™ ICM to detect  arrhythmias 
with various pre -specified characteristics. In addition, the programmer allows the physician to view, 
save, and print the ECG records currently held within the Reveal LINQ ™ ICM.  
 
 
Figure  5: Medtronic  2090 Programmer  
The Medtronic  2090  Programmer  with  the investigational  software  will be used  to download  the LINQ 
HF or ALLEVIATE -HF investigational RAMware  onto the LINQ ™ device.  The investigational RAMware is 
required  to activate additional  sensors  in the Reveal  LINQ ™ ICM.  The software  will be loaded  onto  the 
2090 programmers designated for clinical use only. The 2090 programmer with the investigational 
software will allow the ability to download and remove the RAMware onto and from the device. In 
addition, the 2090 programmer will be used during the study activities as well.  
7.1.5  Medtronic  Investigational  RAMware  
[IP_ADDRESS]  LINQ  HF Investigational  RAMware  
The LINQ HF investigational RAMware is required to activate additional sensors in the Reveal LINQ ICM 
(pre-TruRhythm) to allow for collection of device data needed for potential detection of early COPD 
events. In addition to the existing diagnostic data normally stored in the device, the LINQ H F 
investigational RAMware enables the Reveal LINQ ™ hardware to collect and store additional sensor 
data,  including  impedance,  temperature,  activity,  R-R interval,  R-wave  amplitude,  posture  change  count 
(based on z -axis accelerometer values) and x, y, and z -axis accelerometer measurements.  The device  

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795315]  amplitude 
and every 5 minutes for R -R intervals, posture change count, and x, y, and z -axis accelerometer values.  
In addition, impedance measurements are collected when the Patient Assistant is used.  
[IP_ADDRESS]  ALLEVIATE -HF Investigational  RAMware  
The ALLEVIATE -HF investigational RAMware is required to activate sensors in the Reveal LINQ ICM with 
TruRhythm  to allow  for collection  of device  data  needed  for potential  detection  of early  COPD  events.  In 
addition to the existing diagnostic data normally stored in the device, the ALLEVIATE -HF investigational 
RAMware enables the Reveal LINQ ™ to record and store impedance, temperature, R -R interval, R -wave 
amplitude, x, y, and z -axis accelerometer measurements and posture change count periodically. The 
RAMwa re will calculate the respi[INVESTIGATOR_600483].  
 
7.1.[ADDRESS_795316], on 
experiencing  symptoms  potentially  indicative  of a cardiac  event,  to manually  trigger  the LINQ ™ ICM to 
collect and store an ECG record.  
The Reveal  Patient  Assistant  is intended  for unsupervised  patient  use away  from  a hospi[INVESTIGATOR_389966].  The 
Patient Assistant activates the data management feature in the Reveal LINQ ™ ICM to initiate recording 
of cardiac event data in the implanted device memory. Additionally, the investigational RAMware 
enables the storage of a short segment of impedance  signal when the Reveal  Patient Assistant device is 
used.  
The subjects  will be asked  to press  the Patient  Assistant  whenever  they  experience  increased  difficulty 
of breathing not related to an activity. In addition, the subjects may be asked to press the Patient 
Assistant device during the Optional In -Office F/U study visit.  
Figure  6: Patient  Assistant  
 

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 24 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 7.1.7  MyCareLink  ® Home  Monitor  
The MyCareLink®  Home  Monitor  is a device  that enables  the device  diagnostic  data  (which  includes  ECG 
data) to be transmitted directly from the implanted Reveal LINQ ™ device to the Medtronic CareLink® 
Network for review by [CONTACT_099]. The additional data that is stored in the device by [CONTACT_600515] a manual CareLink transmission but will not be 
available for review by [CONTACT_3725] a nd or physician.  
Figure  7: MyCareLink  Patient  Monitor  
 
 
 
7.1.[ADDRESS_795317] electrical heart signals from electrode 
patches attached to the skin (ECG) as well as from the cardiac device (EGM).  There are no 
contraindications for the use of a DR220 Holter monitor. The Holter monitor will be used in accordance 
with its labeling.  Only trained study personnel should apply the monitors.  
The data obtained by [CONTACT_600516]. After the recording is 
complete,  the data  must  later  be downloaded  to a compatible  NorthEast  Monitoring,  Inc. Holter  analysis 
system to be analyzed. No personal information will be entered and collected by [CONTACT_91511]220 recorder.  
The DR220 Holter Recorder used in this study is a portable ECG device able to collect telemetry signals 
and marker  channel  information  from  any Medtronic  device  for up to [ADDRESS_795318] with a Medtronic ICM.  For the purposes of this study, the intended use of 
the Holter Recorder is to acutely uplink continuous impedance and ECG signals that will be collected by 
[CONTACT_600517].  Since  only  the device  data  uplink  feature  of the Holt er 
will be used in this study, the device antenna will only be used, and no ECG electrodes will be used.  

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 25 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Figure  8: DR220  Holter  
 
 
7.1.9  EMFIT  QS + CARETM Bed Monitor  
The commercially available EMFIT QS+CARETM bed monitor is a real -time occupancy and movement 
activity  monitor  with  health  data  tracking  that is placed  under  the mattress.  The monitor  can track  and 
record heart and breathing rate, heart rate variability, sleep time, movement activity, bed exits, sleep 
score and sleep stages. The data collected will be transmitted back to Medtronic through a cellular 
mobile data connection. Medtronic is requesting up to [ADDRESS_795319] the monitor 
under their mattress for the duration of th eir study participation, with no more than 10 subjects per 
site. The bed monitor will be used in accordance with its labeling.  
Figure  9: EMFIT  QS+CARETM Bed Monitor  
 
 
7.2 Manufacturer  
All products  used  in this study  are manufactured  by [CONTACT_13735],  Inc.,  with  the exception  of the DR220 
Holter Monitor and the EMFIT QS + CARETM Bed Monitor  

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 26 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 7.3 Packaging  
Labelling  for the LINQ  HF and ALLEVIATE -HF investigational  RAMware  will be provided  under  separate 
cover. Labelling for all other market approved system components can be found with each package 
insert and/or are available on http://manuals.medtronic.com.  
The LINQ  HF and ALLEVIATE -HF investigational  programmer  software  will be distributed  electronically 
through the Software Distribution Network (SDN), therefore physical media labeling is not required.  
Once the LINQ HF and ALLEVIATE -HF investigational software is installed on a CareLink [ADDRESS_795320] frequent exacerbations (one requiring hospi[INVESTIGATOR_059], ED visit, or urgent care visit, or at least two 
others in the past year). The Reveal LINQTM device with investigational LINQ HF or ALLEVIATE -HF 
RAMware  download  will be used  in study  subjects  to collect  and characterize  Reveal  LINQTM derived  data 
from patients with COPD by [CONTACT_600518].  
7.[ADDRESS_795321]  Use 
The market  released  Reveal  LINQTM and investigational  LINQ  HF/ALLEVIATE -HF software  and RAMware 
will be used in accordance with their respective product manuals, which are available under separate 
cover.  
7.[ADDRESS_795322] information including, but 
not limited to, date, model/serial number, and expi[INVESTIGATOR_600484], subject ID of 
implanted subject, date implanted, date explanted (if applicable), date returned to Medtronic and 
reason for return (if applicable), reason for and method of destructio n/disposal for explanted 
components not returned to Medtronic (if applicable), and name [CONTACT_600564]/disposal (if applicable). Medtronic will perform periodic reconciliation of investigational 
product to ensure traceabili ty. 
 
The following  products  will be tracked  on an accountability  log: 
• Reveal  LINQTM device  
• 2090  Programmer  with  the Investigational  Software  
• Patient  Assistants  provided  to sites  for use during  in-office  visits  
• Holter  DR220  
• EMFIT  QS+CARETM bed monitor  
 
The MyCareLink Patient Monitors and Patient Assistant devices provided to subjects as part of their 
Reveal  LINQ  ICM system  will not be considered  investigational  in the study  and will not be tracked  on a 
product accountability eCRF.  
7.[ADDRESS_795323] should be returned to Medtronic for analysis according to local laws and 
regulations.  If the products  are explanted  but not returned,  a justification  is required  to be reported  on 
the appropriate eCRF(s) and/or disposition log(s). The Product Distribution Logs must be updated for 
explanted devices. To receive a Returned Product Mailer Kit, please contact [CONTACT_600519]. All unused  product  must be returned  to Medtronic  upon  study  closure at 
the center.  
The Product  Disposition  Logs  must  be updated  with  the final  device  disposition.  
Table  4: Study  Product  Disposition  
 
Model 
Number  Component  Return  to 
MDT at 
Center  
Closure  Disposal  after 
Each Use Investigational 
RAMware 
Removal  Investigational 
Software 
Removal  
LNQ11  Reveal  LINQTM X 
(Explant 
Only)  X 
(Study  Exit)  
[ZIP_CODE]  MyCareLink® Monitor  X    
[ZIP_CODE]  Patient  Assistant*  X    
2090 2090 Programmer  with 
Investigational  
Software   
X1   
X 
DR220  Holter  X    
IP-9260 EMFIT  QS+CARE ™ Bed 
Monitor  X    
[ADDRESS_795324] will  be labeled Investigational.  
*Patient  Assistants  that will be used  at the sites  are required  to be returned  to Medtronic  at the end of 
the study.  
7.[ADDRESS_795325]  Accountability  
The following  section  details  tracking  of all clinical  investigation  study  components.  Study  components 
will be distributed to a center only when Medtronic has received all required documentation and has 
notified the center of center activation.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 29 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 7.11.1  CareLink  Programmer  
The 2090 Programmers used in the study are commercially available, however once the investigational 
Software is downloaded onto the 2090 Programmers in this study, the 2090 Programmer becomes 
investigational. The 2090 Programmer disposition logs will be located in the database  and will be used 
for tracking  of all programmers  downloaded  with  the investigational  software.  When  the investigational 
software is installed on or removed from the programmer(s), the programmer disposition log must be 
updated.  
7.11.2  Reveal  LINQ  ICM 
The Reveal LINQ ™ device used in this study are commercially available, however once the 
investigational RAMware is downloaded to the device, the device will be considered an investigational 
product. The  investigational device will  be tracked  via device  disposition logs in the database.  When the 
investigational  RAMware  is installed  on or removed  from  the device(s),  these  changes  must  be recorded 
on the applicable eCRF(s) (e.g. Insertion Procedure, Scheduled Follow -up or Study Exit eCRF).  
7.11.3  Patient  Assistant  
The Patient  Assistant  device(s)  provided  to sites  for use during  in-office  study  visits  will be tracked 
on the Patient  Assistant  device  accountability  eCRF.  Use of the Patient  Assistant  in the study  is not 
considered investigational. Patient Assistant devices provided to subjects as part of their LINQ  
ICM system  will not be tracked.  
7.11.4  Holter  DR220  
The Holter  DR220  will be tracked  on the DR220  Holter  accountability  eCRF.  
7.11.5  EMFIT  QS+CARETM bed monitor  
The EMFIT  QS+CARETM bed monitor  will be tracked  on the EMFIT  QS+CARETM bed monitor  accountability 
eCRF.  
 
8.  Study  Site Requirements   
8.1 Investigator/Investigation  Site Selection  
All investigators  or co-investigators  managing  the subject’s  COPD  must  be qualified  practitioners  and 
experienced  in the diagnosis  and treatment  of subjects  with  COPD.  All implanting  physicians  must  be 
experienced and/or trained in the handling of Reveal LINQTM ICM devices.  
The role of the principal  investigator  [INVESTIGATOR_600485]-to-day conduct  of the clinical 
investigation as well as ensure data integrity and the rights, safety and well-being of the subjects 
involved in the clinical investigation.  
The principal  investigator  [INVESTIGATOR_67417]:  
• Be qualified  by [CONTACT_8640],  training,  and experience  to assume  responsibility  for the proper 
conduct of the clinical investigation  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 30 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Be experienced  in the field  of application  and training  in the use of Reveal  LINQTM ICM 
devices  
• Disclose  potential  conflicts  of interest,  including  financial,  that interfere  with  the conduct  of 
the clinical investigation or interpretation of results  
• Be able  to demonstrate  that the proposed  investigational  study  site: 
▪ Has the required  number  of eligible  subjects  needed  within  the recruitment  period.  
▪ Has one or more  qualified  investigators,  a qualified  investigational  study  site team 
and adequate facilities for the foreseen duration of the clinical investigation.  
Study  site personnel  training  will be completed  and documented  prior  to participation  in this study.  
8.2 Study  Site Activation  
During  the activation  process (prior  to subject enrollment),  Medtronic  will train  study site  personnel  on 
the clinical  investigation  plan,  on relevant  standards  and regulations  (if needed),  informed  consent,  and 
on data collection and reporting tools. If new members join the study site team, they will receive 
training on the applicable study requirements relevant to their role before contributing to the study.  
Prior  to performing  study  related  activities,  all regulatory  requirements  shall  be fulfilled,  including,  but 
not limited to the following:  
• EC approval  (and  voting  list, as required  by [CONTACT_169291])  of the current  version  of the CIP and 
IC. 
• RA approval  or notification  (as required  per local  law) 
• Fully  executed  CTA 
• Financial  disclosure  (if applicable)  
• CV of investigators and key members of the investigation study site team (as required). The 
signature  [CONTACT_600565]  3 years  prior  to the date  of activation  of the study 
site. 
• Documentation  of delegated  tasks  
• Documentation  of study  training.  
• Additional  requirements  imposed  by [CONTACT_56819],  the EC and RA shall  be followed,  if 
appropriate.  
In addition,  all participating  study  site staff  must  be trained  on the current  version  of the CIP as well as 
on the applicable study requirements depending on their role and must be delegated by [CONTACT_1961] [INVESTIGATOR_180984].  
Medtronic  will provide  each  study  site with  documentation  of study  site/investigator  readiness;  this 
letter must be received prior to performing study related activities.  
8.3 Role  of the Sponsor  Representatives  
Sponsor  representatives  will provide  support  as required  for the study  under  supervision  of the Principle 
Investigator, including:  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 31 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Provide  study  training,  including  but not limited  to training  on the: CIP, Informed  Consent 
process, data collection tools, and regulations  
• Technical  support  in installing/uninstalling  the programmer  software  into/from  the Programmer 
manually or via the SDN  
• Technical  support  at all in-office  study  visits  under  the supervision  of the Principle  Investigator, 
including device programming, but no data entry on eCRFs shall be performed by [CONTACT_600520]  
• A trained  Medtronic  representative  may  support  a study  investigator  at the Insertion  Visit  by 
[CONTACT_600521]  
• Sponsor  representatives  may  conduct  monitoring  and auditing  activities  for this study  
 
9.  Selection  of Subjects   
9.[ADDRESS_795326]  frequent 
exacerbations (one requiring hospi[INVESTIGATOR_059], ED visit, or urgent care visit, or at least two others in the 
past year). Inclusion and Exclusion criteria are listed below.  
9.[ADDRESS_795327]/IRB  and Medtronic  approval  of this Clinical  Investigation  Plan,  the informed  consent  form 
and any other applicable documents must be obtained prior to enrolling subjects in the study.  
Medtronic  will provide  each  study  center  with  documentation  of study  center/investigator  readiness; 
this letter must be received prior to subject enrollment.  
When a patient and the principal investigator [INVESTIGATOR_166657], as required, have personally 
signed  and dated  the informed  consent  form,  the patient  is considered  a subject  enrolled  in the study. 
Subjects must provide informed consent before any study related procedures occur. The date the 
subject signed the informed consent form and data protection authorization as required by [CONTACT_600522]’s medical records.  
9.3 Inclusion  Criteria  
• Patient  is ≥ 45 years  old 
• Patient  (or patient’s  legally  authorized  representative)  is willing  and able  to provide  written 
informed consent  
• Patient  is willing  and able  to comply  with  the protocol,  including  follow -up visits,  diary  submissions 
and CareLink transmissions  
• FEV 1 (post  bronchodilator)  ≤ 70%  of predicted  
• Current  or former  smoker  with  lifetime  cigarette  consumption  of > 10 pack -years  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 32 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • One COPD exacerbation in the previous 12 months requiring hospi[INVESTIGATOR_059], urgent care or 
emergency  department  visit for respi[INVESTIGATOR_600486] 
12 months requiring antibiotics and/or corticosteroids for respi[INVESTIGATOR_1856]  
• The patient’s  medical  records  must  be accessible  by [CONTACT_600507] -up period  
9.4 Exclusion  Criteria  
• Less than 30 days from diagnosis of a COPD exacerbation as defined as taking antibiotics and/or 
corticosteroids  for respi[INVESTIGATOR_23908],  hospi[INVESTIGATOR_059],  urgent  care  or emergency  department 
visit for respi[INVESTIGATOR_4375]. *  
• Less than 30 days from diagnosis of a HF event as defined as any cardiovascular -related (including 
hypervolemia) Health Care Utilizations (HCUs) for any one of the following events: Admission with 
primary diagnosis of HF or Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration 
at any one of the following  settings:  Admission  with  secondary/tertiary  diagnosis  of HF, Emergency 
Department, Ambulance, Observation Unit, Urgent Care, or HF/Cardiology Clinic  
• Active  respi[INVESTIGATOR_600470]/or  corticosteroids  
• Class  IV heart  failure  
• Clinical  diagnosis  of unstable  angina,  bronchiectasis,  or cystic  fibrosis  
• Any concomitant  condition  that might  endanger  the patient  through  participation  in the study  or 
interfere with study procedures, as assessed by [CONTACT_093]  
• Patient  is pregnant  (all females  of child -bearing  potential  must  have  a negative  pregnancy  test 
within 1 week of enrollment)  
• Patient  is enrolled  in another  study  that could  confound  the results  of this study,  without 
documented pre -approval from a Medtronic study manager  
• Patient  has an existing  or planned  implantation  of Medtronic  IPG, ICD, CRT-D or CRT-P device in  the 
near future  
• Patient  has an existing  and active  insertable  cardiac  monitor,  regardless  of manufacturer  # 
• Concurrent  disease  with  life expectancy  less than  1 year  
 
* This exclusion  criterion  has been  removed  as documented  in the Intended  CIP deviation  dated  13- 
OCT-2021  
# This exclusion  criterion  has been  updated  to “Patient  has an active  non-Medtronic  insertable  cardiac 
monitor” in the Intended CIP deviation dated [ADDRESS_795328]-2021  
 
10. Study  Procedures   
10.1  Schedule  of Events  
A patient  will be  considered enrolled in  the study once they sign and date the  Informed Consent.  The 
subjects  will be followed  via trimonthly  phone  calls  and potentially  at one in-office  visit at some  point 
during  study participation.  In addition,  the subjects  will be completing  their  weekly diary  submissions 
and bi -weekly manual device transmissions.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 33 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 10.2  Data  Collection  
The requirements  for data  collection  and study  procedures  by [CONTACT_600523]  5 below.  
Table  5: Data  Collection  and Study  Procedure  Requirements  at Subject  Visits  
 
 
STUDY  PROCEDURE  
 
Baseline  
 
LINQTM 
Insertion  
Weekly  
Subject  
F/U Phone 
Call (every 
3 months)  
In Office 
F/U 
(optional)  
Study  Exit 
Patient  Informed  Consent  X      
Inclusion/Exclusion  Assessment  X      
Medical  History  X      
Demographics  X      
SGRQ  (St. George’s  Respi[INVESTIGATOR_21606])  X     X 
BCSS  (Breathlessness,  Coughing  and Sputum  Scale)    X    
Baseline  Measurements  X    X  
Medication  Assessment  X   X X X 
PRN  Medication  Assessment    X    
Patient  Assistant  Activity      X  
Laboratory  results  X     X 
Final  system  configuration   X     
Insertion  procedure  information   X     
LINQ  HF or ALLEVIATE -HF RAMware  download  onto  LINQ ™ 
device   X     
Device  Data  Interrogation  (Save  to media  via USB)   X   X X 
Standard  Forced  Spi[INVESTIGATOR_600487]  (pre and post  bronchodilator)  
X      
Standard  Forced  Spi[INVESTIGATOR_600487]  (pre and post  bronchodilator)  
while wearing Holter       
X  
Spi[INVESTIGATOR_600488]      X  
Chest  X-ray     X  
LINQ  HF or ALLEVIATE -HF RAMware  removal  from  LINQ ™ 
device and optional explant       X 
Adverse  Events  (including  AEs with  a fatal  outcome)   
 
As they  occur  Device  Deficiency  
System  Modification  
Study  Deviations  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 34 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 10.3  Scheduled  Follow -up Visit  Windows  
Because  the study  is estimated  to be completed  in approximately  33 months  (includes  approximately  [ADDRESS_795329] and up to 1 month 
between enrollment and insertion), window dates are provided for 33  months.  If follow -up phone calls 
need to continue beyond 33 months, the windows will continue at 90 -day intervals with ±[ADDRESS_795330] be accompanied by a deviation.  
Table  6: Scheduled  Visit  Windows  
 
 
Study  Follow - 
up Visit  Window  
(Calculated  days  post  LINQ™ device  insertion)  
Window  Start 
(# of days)  Target  
(# of days)  Window  End 
(# of days)  
3-Month  [ADDRESS_795331] and the 
investigator (or authorized designee as required by [CONTACT_472543] [ICF]) have each 
personally signed and dated the ICF.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795332]’s  voluntary  agreement  to 
participate  in a particular  clinical  study  after  information  has been  given  to the subject  on all aspects  of 
the clinical study that are relevant to the subject’s decision to participate. This process includes 
obtaining an ICF and an Authorization to Use and Disclose Personal Health Information/Research 
Authorization/other privacy language as required by [CONTACT_2371] t hat has been approved by [CONTACT_3452]’s 
Institutional Review Board/Ethics Committee (IRB/EC) and signed and dated by [CONTACT_423].  
Investigators  shall  consider  all subjects  who  meet  eligibility  requirements  for study  participation  to avoid 
any bias in the subject population.  Prior to enrolling subjects, approval of the CIP, ICF, and any other 
written study information to be provided to the subjects must have been obtained from each site’s 
IRB/EC.  The document(s) must be controlled (i.e. versioned and dated) to ensure it is clear which 
version(s) were approved by [CONTACT_1201]/EC.  Any adaptation of the sample ICF must be reviewed and 
approved by [CONTACT_169267]/EC reviewing the application prior to enrolling the subject.  
The investigator must notify the subject of any significant new findings about the study that become 
available  during  the study  which  are pertinent  to the safety  and well-being  of the subject,  as this could 
impact  a subject’s  willingness to participate in  the study.  If relevant, approval  may be requested from 
subjects to confirm their continued participation.  
Refer  to Section  18.[ADDRESS_795333]  be conducted  by [CONTACT_62674]  [INVESTIGATOR_022]/her  authorized  designee,  and the 
ICF and Authorization to Use and Disclose Personal Health Information/Research Authorization/other 
privacy language as required by [CONTACT_248974] a language, he/she is able to read 
and understand.  The process of obtaining informed consent must be conducted without using coercion 
or undue improper influence on or inducement of the subject to participate by [CONTACT_600524].  The informed consent process shall not waive or appear to waive subject’s legal rights. 
The language used shall be as non -technical as possible and must be understandable to the subject and 
the impartial witness, where applicable.  
The subject must have ample time and opportunity to read and understand the ICF, to inquire about 
details  of the study,  and to decide whether  to participate in  the clinical  study.  All questions  about  the 
study should be answered to the satisfaction of the subject.  
When the subject decides to participate in the clinical study, the ICF must be signed and personally 
dated  by [CONTACT_600525]. If applicable, the witness shall also  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795334], and that informed consent was freely given.  
A copy of the ICF and the Authorization to Use and Disclose Personal Health Information/Research 
Authorization/other  privacy  language,  signed  and dated  as required  by [CONTACT_2371], must  be provided  to the 
subject.  
If informed consent is obtained the same day the subject begins participating in study -related 
procedures, it must be documented in the subject’s case history that consent was obtained prior to 
participation  in any study -related  procedures.  It is best  practice  for the informed  consent  process  to be 
documented in the subject’s case history, regardless of circumstance.  
In the event the subject cannot read and/or write, a  witnessed (impartial third party) informed consent 
will be allowed.  In this situation, an independent witness must be present throughout the informed 
consent  process.  The written  informed  consent  form  and any other  information  shall  be read  aloud  and 
explained to the prospective subject.  The subject should “make his/her mark” (sign or otherwise 
physically mark the document so as to indicate consent) on the ICF as well.  The witness must also sign 
and perso nally date the ICF attesting that the information was accurately explained, and that informed 
consent was freely given.  Detailed documentation of the consent process must be recorded in the 
subject’s  case history.  The ICF should document a supervised oral  process  was used for  communication 
with the prospective subject and the specific means by [CONTACT_131475].  
The ICF and Authorization to Use and Disclose Personal Health information/Research 
Authorization/other privacy language as required by [CONTACT_600526]. 
Any Medtronic  Field  personnel  who  support  the Reveal  LINQTM ICM insertion  procedure  must  be able  to 
review the subject’s original signed and dated ICF and verify its completeness prior to proceeding with 
the insertion.  In the event the Medtronic Field personnel identify informed consent as being 
incomplete, the study procedure will not be allowed to occur until the consent of the subject can be 
adequately and appropriately obtained.  
10.[ADDRESS_795335] (or 
the subject’s authorized/designated representative or guardian) signed the IC and Data Protection 
Authorization,  as required  by [CONTACT_2371], must  be documented  in the subject’s  medical  records.  Enrollment  can 
be a stand -alone visit or can occur on the same day as the baseline visit. Once consent is obtained, 
report adverse events/deaths, study deviations and subject exits as they occur.  
10.[ADDRESS_795336]  enrollment,  a baseline  assessment  will be performed.  The baseline  visit can be a 
standalone  visit or can be performed  on the same  day as the  LINQ ™ ICM insertion  but prior  to the 
insertion procedure.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 37 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 The following  information  is required  to be collected  at the baseline  visit:  
• Inclusion/exclusion  criteria  assessment  (including  pregnancy  test if the subject  is of 
childbearing potential)  
• Medical  history  
• Medication  assessment  
• Demographics  
• St. George’s  Respi[INVESTIGATOR_21606]  
• Baseline  Measurements  
• Standard  Forced  Spi[INVESTIGATOR_105186]  (pre and post  bronchodilator)  (if it hasn’t  been  done  in 
the past 6 months)  
• Lab Results:  Creatinine,  Brain  natriuretic  peptide  (BNP)  OR N-terminal  brain  natriuretic  peptide 
(NT-proBNP), White Blood Cells, and Eosinophils  
• Study  deviations  
• Adverse  events  
10.[ADDRESS_795337]  occur  within  30 days  of enrollment  or baseline  assessment  and will 
be performed in accordance with the Medtronic Reveal LINQ ™ implant instructions. The recommended 
implant locations are located in Figure 10 below. Physicians should follow the implant manuals when 
performing the Reveal LINQ ™ implant.  
 
 
Figure  10: Recommended  Insertion  Locations  
After  the Reveal  LINQ ™ device  is inserted,  the LINQ  HF or ALLEVIATE -HF investigational  RAMware  will be 
downloaded to the device via the 2090 programmer depending on the type of the Reveal LINQ device 
(see Table 7 below).  

Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 38 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Table  7. Investigational  RAMware  compatibility  
 
Reveal  LINQ  (pre -TruRhythm)  Reveal  LINQ  with  TruRhythm  
LINQ  HF RAMware  ALLEVIATE -HF RAMware  
 
The following  procedures  and data collection  are required  at the insertion  visit: 
• LINQTM insertion  procedure  
• LINQTM system  and procedure  information  
• LINQ  HF or ALLEVIATE -HF Investigational  RAMware  download  
• Device  Interrogation  (save  to media  via USB)  
• Adverse  events  (if applicable)  
• Device  deficiencies  (if applicable)  
• Study  deviations  (if applicable)  
 
 
10.8.1  Device  Programming  Requirements  
Once the LINQ ™ device is inserted into the subject, the physician is recommended to choose "AF 
management.”  This will automatically  program  the device  to the nominal  settings  for the different 
detectors.  
10.9  EMFIT -QS+CARE ™ Bed Monitor  
Up to [ADDRESS_795338] once a week or when their COPD symptoms change, 
which can be more often than once per week. The diary comprises of the Breathlessness, Coughing and 
Sputum  Scale  Questionnaire  (BCSS)  and PRN  medication  tracking.  The subject  will receive  instructions  on 
how to complete the weekly diary, refer to Section 18.3 for more details.  
The diary data will be reviewed alongside the CRF and LINQ ™ device data to track potential COPD 
events.  The subject  diary  data  will not be reviewed  for any reportable  AEs since  all pertinent  AEs will be 
formally collected at the scheduled follow up visits.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 39 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 10.11  Bi-Weekly  CareLink  Transmissions  
Subjects will be provided with a MyCareLink Patient Monitor and enrolled in the Medtronic CareLink 
network, and will be instructed on how to set up their monitor to support automatic nightly 
transmission of their device data. In addition, subjects are requ ired to perform a manual device 
transmission  bi-weekly  (every  14 days)  from  the time  they  are enrolled  in the study  until  they  are exited 
from the study. This transmission is critical as data collected by [CONTACT_600527] [ADDRESS_795339] missed their manual transmission.  
A monthly  study  deviation  will be required  if 2 straight  bi-weekly  transmissions  are missed,  unless  a 
device  interrogation  file for an interrogation  occurring  within  the required  timeframe  is provided  to 
Medtronic.  
10.12  Scheduled  Follow -up Visits  
10.12.1  Phone  Follow -up Visit  (every  3 months)  
Subjects  will complete  telephone  follow -up visits  every  three  months  post  device  insertion.  These  visits 
may also be conducted in -person if desired, e.g. in the case the subject is already in -office for another 
reason. The following information is required to be collected at these visits:  
• Manual  data  transmission  reminder  
• Medications  Assessment  
• Adverse  Events  
• Device  deficiencies  
• Study  deviations  
• System  modification  
10.12.2  In-Office  Follow -up Visit  (optional)  
The optional in -office follow -up visit can be conducted at any time during study participation, except 
within  [ADDRESS_795340]  30 
subjects complete this visit.  
The following  information  is required  to be collected  at the In-Office  scheduled  follow -up visit:  
• Baseline  measurements  
• Medications  Assessment  
• Initial  device  interrogation  (pre visit procedures)  (save  to media  via USB)  
• Spi[INVESTIGATOR_600489]  
o DR220  Holter  recommended  to be used  during  test 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 40 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Standard  Forced  Spi[INVESTIGATOR_77572] (pre and post  bronchodilator)  
o DR220  Holter  recommended  to be used  during  test 
• Final  device  interrogation  (post  visit procedures)  (save  to media  via USB)  
• Chest  X-ray (if no previous  PA or AP and Lateral  chest  x-ray with  LINQ  device  in image)  
• Adverse  events  (if applicable)  
• Device  Deficiencies  (if applicable)  
• Study  Deviations  (if applicable)  
• System  Modifications  (if applicable)  
10.[ADDRESS_795341] for tidal volume will be completed twice at the optional in -office visit accompanied 
with  breathing  maneuvers  and with  the Holter  applied.  Oftentimes,  one of these  tests  is referred  to as 
the Maximum Voluntary Ventilation (MVV) Test, however in this study, it will be performed with 
specified  breathing  maneuvers  outlined  in Figure  [ADDRESS_795342] does not need  
to be  repeated  (data  from the prior  spi[INVESTIGATOR_600490]).  The forced  spi[INVESTIGATOR_600491] a test pre bronchodilator and post bronchodilator. It is requested of the site  
to record at most the first eight tries of each test (pre and post bronchodilator).  
At the optional in -office visit, a Holter will be recommended to be worn during the test. In addition, the 
subjects  may  be asked  to press  the Patient  Assistant  device  during  the assessment.  Refer  to section  18.[ADDRESS_795343]  X-ray (i.e. PA or AP and Lateral)  displaying  the location  of the LINQ  device  must  be collected.  If 
the subject has not had a prior chest X -ray with the LINQ device in image, then a chest X -ray will be 
completed (can occur any time after LINQ insertion but must occur before study exit).  
10.[ADDRESS_795344] some additional information from the LINQ ™ 
device. The DR220 Holter Recorder used in this study is a portable ECG device able to collect 
continuously telemetered signals from any Medtronic device for up to [ADDRESS_795345] at the optional  in-office visit,  or else the  Holter  does  not 
store any data.  
Since  only  the device  data  uplink  feature  of the Holter  will be used  in this study,  the device  antenna  will 
only be used, and no ECG electrodes will be used.  Please refer to Section 18.3 for more details.  
10.16  Device  Interrogation  
For all visits occurring in the office, a full “interrogate all” final device interrogation file (.pdd) must be 
obtained  and saved  in a digital  format  (USB).  The original  file must be  stored  at the site  and a copy  sent 
to Medtronic. It is recommended that data are not cleared during any interrogation. The interrogation 
should be conducted at the end of the visit.  
10.17  System  Modification  
A system modification will be reported in the event the device requires invasive modification (e.g., 
device  explant  (other  than  at study  exit),  device  reposition).  In the event  of a system  modification,  the 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795346]  will remain  unchanged.  For a system  modification  the following 
activities are required:  
• Complete  the System  Modification  eCRF  
• Device  interrogation  (media/USB)  
• Adverse  events  (if applicable)  
• Device  Deficiencies  (if applicable)  
• Study  Deviations  (if applicable)  
If the device is taken out of service (e.g. explanted) and a replacement will not be implanted, or the 
replacement is not a study approved device, the subject must be exited from the study after all device 
and/or  procedure  related  AEs have  been  resolved  or remain  unresolved  with  no further  action  planned.  
All explanted  product  (device)  should  be returned  to Medtronic  for analysis  when  permissible  by [CONTACT_358598]. See Section 7.[ADDRESS_795347] disposition details.  
10.18  Medications  Assessment  
The name,  dose,  frequency  and route  of all medications  will be collected  at all visits.  Changes  to 
medications will be captured on the Medication Log eCRF.  
There are no medications that are required for this study although some medications may be 
administered  in treating  specific  conditions  at the discretion  of the physician.  The only  medications  that 
are excluded from use during this study are investigational.  
10.19  Assessment  of Safety  
All LINQTM system and procedure related adverse events (AEs), all serious adverse events (SAEs), all 
Pulmonary  related  AEs and all Cardiovascular  related  AEs will be collected  throughout  the duration  of a 
subject’s  participation  in the study,  beginning  at the  time  of informed  consent.  Additionally,  any device 
deficiencies related to the LINQTM system will be collected. Adverse events and device deficiencies will 
be reported to Medtronic via completion of eCRFs. See section 12.0 for additional details.  
LINQTM system  and procedure  related  AEs reported  in the study  will be summarized  as an ancillary 
objective. Additionally, reported device deficiencies will be summarized.  
10.20  Review  of Data  Recorded  by [CONTACT_600528] ™ data  derived  from  the investigational  RAMware  will not be viewable  to the site.  The 
standard arrhythmia data from the LINQ ™ device will be viewable via CareLink.  
10.[ADDRESS_795348] data will be collected on electronic case report forms (eCRFs) via a web -based remote data 
capture  (RDC)  system.  The investigator  must  ensure  accuracy,  completeness  and timeliness  of the data  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795349] be signed and dated by a member of the 
investigational  site team  with  a statement  that it is a true  reproduction  of the original  source  document.  
Device  data  from  transmissions  will be uploaded  to secure  servers.  Media/USB  data  collected  at office 
visits will be sent to Medtronic.  Upon receipt, device data will be maintained with databases and 
retrieved for analysis and reporting.  
Refer  to section  16.[ADDRESS_795350] in an emergency or in unforeseen situations 
beyond the investigator’s control (e.g. subject failure to attend scheduled follow -up visits, i nadvertent 
loss of data due to computer malfunction, inability to perform required procedures due to subject 
illness).  
For medically justifiable conditions which preempt a subject’s ability to complete a study -required 
procedure,  it may be permitted to report only one deviation  which will apply to all visits  going forward. 
This may  also apply  for other  unforeseen  situations  (e.g.  the subject  permanently  refuses  to complete  a 
study  required  procedure  and the data  will not contribute  to the primary  end point  analysis).  However, 
prior approval from Medtronic is required for such situations.  
All study deviations must be reported on the study deviation e -CRF regardless of whether medically 
justifiable,  pre-approved  by [CONTACT_13735],  an inadvertent  occurrence,  or taken  to protect  the subject  in an 
emergency.  The deviation description and reason for deviation must be recorded. Multiple deviations 
of the same type at the same visit may be reported on one e -CRF.  
In the event  the deviation  involves  a failure  to obtain  a subject’s  consent  or is  made to protect the  life or 
physical  well-being  of a subject  in an emergency,  the deviation  must  be reported  to the IRB/EC  as well as 
Medtronic  within  five (5)  working  days.  Reporting  of all other  study  deviations  must comply with  IRB/EC 
policies and/or local laws and/or regulatory agency requirements and  must be reported  to Medtronic as 
soon as possible upon the center becoming aware of the deviation.  Refer to Table  12 for geography  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 44 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 specific  deviation  reporting  requirements  and timeframes  for reporting  to Medtronic  and/or  regulatory 
bodies.  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any 
additional corrective and/or preventive actions (e.g. amend the Clinical Investigation Plan, conduct 
additional  training,  terminate  the investigation).  Repetitive  or serious  investigator  compliance  issues 
may result in initiation of a corrective action plan with the investigator and site, and in some cases, 
necessitate suspending enrollment until the problem is resolved or ultimately terminating the 
investig ator’s participation in the study.  Medtronic will provide site -specific reports to investigators 
summarizing information on deviations that occurred at the investigational site on a periodic basis.  
10.[ADDRESS_795351] until any ongoing AEs related to the Reveal LINQ ™ 
system or procedure are classified by [CONTACT_093], as resolved. The date and reason for subject exit 
must  be reported  to Medtronic  at the earliest  opportunity  via eCRF.  Exited  subjects  will not be replaced. 
Upon exiting from the study, no further study data will be coll ected, or study visits will occur for the 
subject.  All data available through the time of the subject’s exit will be used for analysis. Subjects are 
urged to remain in the study as long as possible but may be exited from the study for any of the 
following situations:  
• Subject  did not meet  inclusion/exclusion  criteria  and was not inserted  with  a LINQTM device  
• LINQTM ICM explanted  and not replaced  with  a new  LINQTM ICM (e.g.  diagnosis  determined, 
suspected infection, subject request, physician determination)  
• Subject  chooses  to withdraw  (e.g.,  consent  withdrawal,  relocation  to another  geographic 
location)  
• Investigator  chooses  to withdraw  a subject  (e.g.,  medically  justified,  inclusion/exclusion  criteria 
not met, failure of subject to maintain adequate study compliance)  
• Implant  attempted,  however  no Reveal  LINQTM was implanted  
• Subject  lost to follow -up 
• Death  
• Study  completion  or termination  
The following  information/procedure  is to be collected/performed  at study  exit:  
• Date  of exit 
• Reason  for exit 
• Medications  Assessment  
• St. George’s  Respi[INVESTIGATOR_600492]  5.0, 
1-DEC-22 Page 45 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Laboratory  results:  Creatinine,  Brain  natriuretic  peptide  (BNP)  OR N- terminal  brain 
natriuretic peptide (NT -proBNP), White blood cells, Eosinophils  
• Initial  Device  Interrogation  (save  to media  via USB)  (prior  to removal)  
• Removal  of the investigational  RAMware  from  the LINQTM device  
• Opting  out of the subject diary  
• Post  Device  interrogation  (save  to media  via USB)  (post  removal)  
• Adverse  events  
• Device  deficiencies  
• Study  deviations  
10.23.[ADDRESS_795352]’s  6-month  follow -up visit is  completed  or 
until official study closure, defined as when Medtronic and/or regulatory requirements have been 
satisfied per the Clinical Investigation Plan and/or by a decision by [CONTACT_131488], 
whichever occurs first.  Subjects will be provided standard medical care by [CONTACT_600529].  
10.23.[ADDRESS_795353]  to follow -up, details  of a minimum  of two attempts 
and the method  of attempt  (e.g.,  one letter  and one phone  record  or two letters)  to contact  [CONTACT_508789]. In addition, follow the regulations set forth by [CONTACT_114021]/EC.  
10.23.[ADDRESS_795354]  Chooses  to Exit (i.e. Revokes  Consent)  
A subject  can withdraw from the study  at any time.  If the subject wishes  to exit from  the study  (i.e. the 
subject revokes consent), the study site is required to document the reason for exit on the Exit CRF. In 
addition,  study  sites  shall  follow  the regulations  set forth  by [CONTACT_600530]. If possible,  the following 
data should be collected prior to subject withdrawal:  
• Reason  for exit 
10.23.[ADDRESS_795355] 
withdrawal if possible:  
• Reason  for subject  withdrawal  
10.23.[ADDRESS_795356] is enrolled/randomized every effort should be made to keep the subject in the study. 
However, it is recognized that there are circumstances where limited data may be collected, or study 
exit will need to occur. In these cases we will consid er either modified data collection requirements 
where  subjects  may  conditionally  disengage  in study  procedures  but data  from  the subject  can still be 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795357]  has not revoked  consent,  or exit when  study  participation  is completely 
ended. In randomized subjects, modified data collection is always preferred over exit.  
Subjects  may  be conditionally  disengaged  from  study  procedures  for any of the following  reasons:  
• Subject chooses to disengage (e.g., follow -up schedule cannot be adhered to, study 
burden  too large,  relocation  to another  geographic  location  but telephone  follow -up still 
acceptable)  
• Investigator  deems  conditional  disengagement  necessary  (e.g.  medically  justified)  
If the subject wishes to disengage from the study, or the investigator deems it necessary, the study site 
is required to document the reason. Prior approval from the study team is required and a Limited Data 
Collection  CRF needs  to be completed.  Data  collection  requirements  no longer  apply,  but study  sites  are 
encouraged to collect as much data as possible on the regular CRFs.  
 
11. Risks  and Benefits   
11.[ADDRESS_795358] -market 
surveillance.  The risk analysis  process  for the LINQ ™ for COPD  study  is being  performed  in accordance 
with ISO [ZIP_CODE], and ensures that the level of residual risk is reduced to as low as possible prior to 
starting the clinical study.  
There  are potential  risks  and side effects  associated  with  a Reveal  LINQ ™ device  implant  and explant 
procedures:  
• Allergic  reaction  or device  rejection  phenomena  including  local  tissue  reaction  
• Excessive  device  migration  (internal  pocket  device  movement  as well as device  externalization)  
• Pocket  infection  
• Erosion  through  the skin 
• Tissue  / vascular  trauma  
Possible  additional  risks  for participating  in this study  include  the following  (although  others  are 
possible):  
• The Reveal  LINQ ™ device  with  investigational  RAMware  download  is investigational  and may  be 
no more effective or less effective than a commercially available Reveal LINQ ™ device system.  
• There  may  be stimulation  effects  from  the impedance  measurements  being  taken  across  the 
Reveal LINQ ™ device electrodes. The amount of current injected as part of the impedance 
measurements has been minimized to very low levels to prevent patient harm.  
• The investigational RAMware feature set will cause current drain on the Reveal LINQ ™ ICM 
device battery. Risk control measures have been implemented and the current projected 
longevity  of a LINQ ™ device  with  investigational  RAMware  shows  a 5 month  decrease  in average  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 47 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 projected  service  life compared  to a LINQ ™ device  without  the RAMware.  The exact  service  life 
of the LINQ ™ device will vary depending on each subject’s use.  
• There may be undesired device interactions with the investigational RAMware, potentially 
resulting in loss of or inaccurate Reveal LINQ ™ data, and/or premature explant. Once the 
investigational  RAMware  feature  set is executed,  periodic  data  integrity  checks  are in place  to 
ensure correct functionality.  
• The Reveal  LINQ ™ device  with  the investigational  RAMware  download  may  present  data  that 
are different than anticipated due to unknown circumstances or medical conditions.  
• There may be other discomforts and risks related to the Reveal LINQ ™ device with 
investigational  RAMware  download  and/or  this study  that are not foreseen  at this time.  
 
 
11.2  Risk Minimization  
As referenced  above, the potential risks  associated  with  the LINQ ™ HF and ALLEVIATE -HF investigational 
RAMware were identified, assessed, evaluated and effectively controlled. Any potential risks associated 
with  this study  are further  minimized  by [CONTACT_600531].  
In addition, investigators will be actively involved in the implantation and regular follow -up of the 
subjects  implanted  with  the Reveal  LINQ ™ with  investigational  RAMware  systems.  At each  office  follow - 
up visit required per protocol (Table 3: Data collection and study procedure requirements at subject 
visits), the Reveal LINQ ™ device will be interrogated, device data collected to verify appropriate device 
function and patient’s health assessed for any adverse events.  
Medtronic  is further  minimizing  the possibility  of risks  by [CONTACT_239057]-clinical 
testing prior to the clinical study, implementing quality control measures into production processes, 
providing guidelines for subject selection and evaluation, and providing adequate instructions and 
labeling.  
Table  8: Potential  Risks  and Risk Minimization  
Potential  Risk Minimization  
ICM Pocket  Infection  from  implant/ 
explant  procedure  or over  duration 
of implant  • Adherence  to international  standards  for sterility  of 
implanted products  
• The product  packaging  designed  to protect  device 
sterility  
• The insertion  procedure  and tools  are designed  to be 
minimally invasive  
• Wound  check  following  implant,  per site’s  practice  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 48 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
Potential  Risk Minimization  
Allergic  reaction  or ICM Rejection 
following implant procedure  • Assessment  of subjects  to ensure  no Allergic  or rejection 
reaction to materials used in incision/insertion tools, 
Reveal LINQ ™ ICM exterior or incision closure method  
• Wound  check  following  implant,  per site’s  practice  
• Close  monitoring  with  follow -up appointments  
• Investigator  discretion  to remove  ICM and report  study 
deviation  
• Use of biocompatible  materials  in the Incision/  Insertion 
Tools  and Reveal  LINQ ™ ICM exterior  patient -contact[CONTACT_600532]  (internal  device 
movement and externalization)  • Training  and Information  for User  on the Reveal  LINQ ™ 
implant technique and incision closure techniques  
• Use of the implant  tools  to create  small  incision  and tight 
pocket  
• Wound  check  following  implant,  per site’s  practice  
• Investigator  discretion  to remove  if deemed  medically 
necessary  
• IFUs  (Instructions  for Use)  provide  information  regarding 
medical procedures and activities which may interact 
with the ICM.  
• Reveal  LINQ ™ ICM design  includes  anti-migration 
features on the header  
Blunt Tissue Injury/Tissue or Vascular 
Trauma,  bleeding  from  implant/  explant 
procedure  • The ICM and implant  procedure  are designed  to be 
minimally invasive.  
• Insertion  Tool  has a stop  position  that prevents  insertion 
of the probe beyond the distance required for implant.  
• Training  on the correct  use of implant  tools  
• Selection  of experienced  investigators  
Pain,  Scarring  from  implant/explant 
procedure or implanted device  • The shape  and small  device  size minimize  the invasiveness  of 
the implant and explant procedures, and the discomfort 
patients may experience from having an ICM.  
• Use of incision  tool will produce  the smallest  incision 
possible for implant  
Toxicity  risks  due to ICM battery  • Battery and device and hermeticity and reliability 
requirements  prevent  leakage  of toxic  substances.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 49 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
Potential  Risk Minimization  
Premature/Unexpected  ICM explant  
/revision  • The projected longevity of a Reveal LINQ ™ device with 
investigational RAMware shows a 5 month decrease in 
average projected service life compared to a LINQ ™ 
device without the RAMware.  The exact service life of 
the LINQ ™ device  will vary  depending  on each  subject’s 
use. 
Electromagnetic  interference  • Design consideration and precautions in place for the 
Reveal  LINQ ™ system  remain  effective  to address  EMI 
risks  
• Information  regarding  EMI (possible  sources  and ways  to 
reduce interference) is provided to the user  
• The system  adheres  to international  standards  for the 
production of RF energy, reducing the probability of 
interference with other equipment.  
Pain  or stimulation  due to electrical 
currents or ICM heating  • Design  controls  in place  to protect  against  leakage  currents  in 
normal and fault conditions  
• Design  controls  are in place  to protect  against  device  heating  in 
normal and fault conditions.  
• The amount of current injected as part of the impedance 
measurements  has been  minimized  to prevent  subject  harm  
Missing/Misleading  information  causing 
inappropriate medical intervention  • The system  uses  data  integrity  checks  to detect  data  corruption 
and notify the clinician  
• The system ensures components are compatible with the 
system  components;  the instructions  for use provide  guidance 
on maintenance of the system (e.g., software/app updates)  
• The system  provides  notifications  to the clinician  regarding 
system status (e.g., patient transmissions, battery status)  
Injury  due to mechanical  device  failure  • Mechanical device integrity requirements were implemented 
and verified.  They  have  been  validated  against  the expected  use 
conditions.  
Security  vulnerability  impacting  device 
settings, data integrity, 
communications, or longevity  • The system  uses  encrypted  communication  to transfer  data  
• The system  detects  unauthorized  messages  and takes  actions  to 
protect itself.  
Denial  of access  to medical  therapy  or 
diagnostic  • The ICM is MRI conditional  
• The system  provides  information  about  the compatibility  of the 
ICM with common medical procedures  
• The system  provides  means  to non-invasively  identify  the ICM, 
so its compatibility can be verified prior to the procedure.  
Failure  to seek  necessary  medical 
attention  • Instructions  for use warns  users  against  use of the ICM system 
as a real -time / emergency monitoring system.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 50 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
Potential  Risk Minimization  
Removal and disposal of system 
components (biohazards, 
environmental/property  damage 
hazards)  • The insertion  tools  are designed  to be easily  disposed  of 
• The IFU provides  guidance  on disposal  of the ICM at the end of 
service  
Undesired  device  interactions  with  the 
investigational RAMware  • Device interactions  analysis to  ensure  there  are no 
undesired  interactions  between  the investigational 
RAMware and the Reveal LINQ ™ device firmware.  
• The investigational  RAMware  is designed  to be automatically 
removed by [CONTACT_600533] a concern for electrical or electromagnetic interference between the LINQ ™ device and 
the other  associated  study  equipment.  Among  the systems  that have  the potential  for electromagnetic 
interference, here are the associated frequencies and characteristics:  
• LINQ ™ – transmits  and receives  Telemetry  B signal  frequencies  for communication  with 
programmer  
• DR220  Holter  – receives  Telemetry  B signal  frequencies  for recording  
• MyCareLink  Home  Monitor  – receives  Telemetry  B signal  frequencies  from  LINQ  and transmits  data 
to the CareLink Network using 3G cellular frequencies  
• Emfit  bed monitor  – the sensor  component  uses  passive  electrical  signals  to collect  motion  from 
the ribbon.  No electrical signal is transmitted to take a measurement.  The data is then 
transmitted from the communication hub using 3G cellular frequencies  
It appears that there should not be any electromagnetic interference from transmission by [CONTACT_600534].  However,  should  it occur,  electromagnetic  interference  can be mitigated  by 
[CONTACT_600535], such as positioning devices to minimize interference.  
There  may  be additional  discomforts  and risks  associated  with  the Reveal  LINQTM device  or participation 
in this study that are not foreseen at this time.  
 
 
11.3  Potential  Benefits  
The Reveal  LINQ ™ for COPD  study  may  offer  no direct  personal  benefit  to individual  subjects.  
Subjects may benefit from continuous arrhythmia monitoring with the Reveal ICM, as this monitoring 
could result in diagnosis of Atrial Fibrillation (or other arrhythmias) and comprehensive evaluation of 
symptoms on an  earlier and more conclusive basis than what would be possible without an implantable 
cardiac  monitor.  Subjects  may  also benefit  from  being  evaluated  more  frequently  in the office  according 
to the study visit schedule.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 51 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 The information gained from this study could result in the improved management of other patients 
receiving  a Reveal  LINQ ™ device  in the future.  Additionally,  information  collected  from  this study  may 
assist in the design of new product(s)/therapy(ies) and/or instructions for use.  
11.4  Risk-Benefit  Rationale  
Since the differences between the Reveal LINQ ™ market -released device and the Reveal LINQ ™ device 
with the investigational RAMware download are minimal, both devices are used in accordance with the 
Reveal LINQ ™ implant manual and/or user manual, as applicable. The risks associated with the device 
are similar  as would  be the case  if the subject  received  a Reveal  LINQ ™ device  outside  the study  context. 
The risks introduced by [CONTACT_600536].  
The study requirements for careful physician selection and training, and in -office visits carry potential 
benefits that might not be present if the subject was not enrolled in the study.  Hence, for individual 
subjects, participation in the study may have greater benefit than risk. Moreover, the value of the 
knowledge to be gained by [CONTACT_241754]. 
Lastly,  the prospective  benefit  to subjects  of having  Reveal  LINQ ™ cardiac  monitoring,  with  the potential 
to diagnose life -threatening arrhythmias, may provide the patient significant clinical benefit.  
 
12. Adverse  Events  and Device  Deficiencies   
Timely, accurate, and complete reporting and analysis of safety information for clinical studies are 
crucial  for the protection  of subjects.  Reporting  and analysis  of safety  data  are mandated  by [CONTACT_600537].  Medtronic  has established  procedures  in conformity  with  worldwide  regulatory 
requirements to ensure appropriate reporting of safety information.  This study will be conducted in 
accordance with these procedures and regulations.  
12.[ADDRESS_795359]’s  participation,  starting  at the time  the informed  consent  form  is signed:  
• All Reveal  LINQTM Procedure  related  AEs 
• All Reveal  LINQTM System  related  AEs 
• All Serious  AEs 
• All Pulmonary  related  AEs 
• All Cardiovascular  related  AEs 
 
Reporting of AEs to Medtronic will occur on an Adverse Event e -CRF, including a description of the 
event, the diagnosis, the date of event onset, the date the site became aware of the event, the 
relatedness  and seriousness  of the event,  diagnostic  tests  and procedures  performed,  actions  taken  as a 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795360]  implant.  In all geographies,  unavoidable  adverse  events,  listed  in Table  9, 
need not be reported unless the adverse event worsens or is present outside the stated timeframe.  
12.2  Device  Deficiency  
Device  deficiency  (DD)  information  will be collected  throughout  the study  and reported  to Medtronic. 
Reporting  of DDs to  Medtronic will  occur  on a device  deficiency  e-CRF. Note  that DDs that  result  in an 
adverse device effect (ADE) to the subject should be captured on an AE CRF only. Device deficiencies 
that did not  lead  to an AE but could have led to a  serious adverse device  effect  (SADE) (i.e., if suitable 
action had not been taken, if intervention had not been made, or if the circumstances had been less 
fortunate) require immediate reporting.  
12.3  Processing  Updates  and Resolution  
For any changes in status of a previously reported AE (i.e. change in actions taken, change in outcome, 
change  in relatedness),  an update  to the original  AE must  be provided.  All reported  adverse  events  must 
be followed  until the  adverse event  has been  resolved, the subject  exits  the study  or until  study  closure, 
whichever occurs first.  At the time of study exit, all collected AEs with an outcome of “not 
recovered/not  resolved”,  “recovering/resolving”  or “unknown”  must  be reviewed  and updates  provided 
as applicable.  
12.4  Definitions/Classifications  
Adverse  event  (AE) and device  deficiency  (DD)  ISO [ZIP_CODE]:2020  definitions  are provided  in Table  below. 
Where the definition indicates “device”, it refers to any device used in the study. This might be the 
device under investigation, or any market released component of the system.  
Table  9: Adverse  Event  and Device  Deficiency  Definitions  
 
General  
Adverse  Event  (AE) 
(ISO [ZIP_CODE]:2020  section  3.2) Any untoward medical occurrence, unintended 
disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in 
subjects, users or  other  persons, whether  or not 
related  to the investigational  medical  device  and 
whether anticipated or unanticipated.  
NOTE:  This definition  includes  events  related  to the 
investigational medical device or the comparator. 
NOTE:  This definition  includes  events  related  to the 
procedures  involved.  NOTE:  for users  or other  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 53 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 persons,  this definition  is restricted  to events 
related to investigational medical devices.  
(ISO [ZIP_CODE]:2020  section  3.2) 
Adverse Device Effect (ADE) 
(ISO [ZIP_CODE]:2020  section  3.1) Adverse event related to the use of an 
investigational medical device. NOTE: This 
definition  includes  adverse  events  resulting  from 
insufficient or inadequate instructions for use, 
deployment, implantation, installation, or 
operation or any malfunction of the 
investigational medical device.  
NOTE:  This definition  includes  any event  resulting 
from use error or from intentional misuse of the 
investigational medical device.  
NOTE:  This includes  ‘comparator’  if the comparator  is a 
medical device.  
Device  Deficiency  (DD)  
(ISO [ZIP_CODE]:2020  section  3.19)  Inadequacy  of a medical  device  with  respect  to its 
identity, quality, durability, reliability, safety or 
performance.  
Note:  Device  deficiencies  include  malfunctions, 
use errors, and inadequate labelling.  
Relatedness  
Procedure  Related  An adverse  event  that occurs  that is directly  related  to 
the insertion or modification of the Reveal LINQ ™ 
system.  
System  Related  An adverse event that results from the presence or 
performance of any component of the Reveal LINQ ™ 
system  (including  the LINQ ™ device,  incision/insertion 
tools, patient assistant and programmer).  
Pulmonary  Related  An adverse  event  associated  with  the lungs  in which 
signs and symptoms are experienced in either the 
upper or lower Respi[INVESTIGATOR_27441] (i.e. COPD, 
Pneumonia, Asthma, Bronchitis, etc.).  
COPD  Event  An adverse  event  where  the underlying  COPD  condition 
exacerbates beyond normal day -to-day variations, 
where an increase in dyspnea, cough, and/or sputum 
production presents with acute onset and necessitates 
supplementing regular COPD medications with 
antibiotics for respi[INVESTIGATOR_600479]/or steroids  
Cardiovascular  Related  An adverse  event  related to the heart  and blood vessels  or 
the circulation.  
Heart  Failure  Event  A heart  failure  event  is defined  as any cardiovascular - 
related (including hypervolemia) Health Care  
Utilizations  (HCUs)  for any one of the following  events.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 54 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 • Admission  with  primary  diagnosis  of HF 
• Intravenous HF therapy (e.g. IV 
diuretics/vasodilators)  or ultrafiltration  at any 
one of the following settings: Admission with 
secondary/tertiary diagnosis of HF, 
Emergency Department, Ambulance, 
Observation Unit, Urgent Care or 
HF/Cardiology Clinic  
Note:  Only  the Sponsor  will be classifying  Heart  Failure 
Event relatedness.  
Not Related  Relationship  to the device  or procedures  can be 
excluded when:  
• The event is not a known side effect of 
the product  category  the device  belongs 
to or of similar devices and procedures;  
• The event  has no temporal  relationship 
with the use of the device or the 
procedures;  
• The serious event does not follow a 
known  response  pattern  to the medical 
device (if the response pattern is 
previously known) and is biologically 
implausible;  
• The discontinuation of medical device 
application  or the reduction  of the level 
of activation/exposure  – when  clinically 
feasible – and reintroduction of its use 
(or increase of the level of 
activation/exposure)  do not impact the 
serious event;  
• The event involves a body -site, or an 
organ  not expected  to be affected  by [CONTACT_5746];  
• The serious event can be attributed to 
another cause (e.g., an underlying or 
concurrent illness/clinical condition, an 
effect  of another  device,  drug,  treatment, 
or other risk factors);  
• The event  does  not depend  on a false 
result given by [CONTACT_292329] (when applicable);  
• Harm  to the subject  are not clearly  due 
to use error;  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 55 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 In order to establish the non -relatedness, not all the 
criteria listed above might be met at the same time, 
depending  on the type  of device/procedures  and the 
event.  
Unlikely  The relationship with the use of the device seems not 
relevant  and/or  the event  can be reasonably  explained 
by [CONTACT_5748], but additional information may be  
obtained.  
Possible  The relationship with the use of the investigational 
device is weak but cannot be ruled out completely. 
Alternative causes are also possible (e.g. an underlying 
or concurrent  illness/  clinical  condition  or/and  an effect 
of another device, drug or treatment). Cases were  
relatedness  cannot  be assessed  or no information  has 
been obtained should also be classified as possible.  
Probable  The relationship  with  the use of the investigational 
device seems relevant and/or the event cannot  
reasonably  be explained  by [CONTACT_239062],  but 
additional information may be obtained.  
Causal  Relationship  The event  is associated  with  the device  or study 
procedures beyond reasonable doubt when:  
• The event is a known side effect of the 
product  category  the device  belongs  to or of 
similar devices and procedures;  
• The event  has a temporal  relationship  with 
device use/application or procedures;  
• The event  involves  a body -site or organ  that 
the device or procedures are applied to or 
the device  or procedures have an  effect  on; 
• The serious event follows a known response 
pattern  to the medical  device  (if the response 
pattern is previously known);  
• The discontinuation of medical device 
application (or reduction of the level of 
activation/exposure)  and reintroduction  of its 
use (or increase of the level of 
activation/exposure) impact on the serious 
event (when clinically feasible);  
• Other  possible  causes  (e.g.,  an underlying  or 
concurrent illness/clinical condition or/and 
an effect of another device, drug, or 
treatment)  have  been  adequately  ruled  out; 
• Harm  to the subject  is due to error  in use; 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 56 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 • The event  depends  on a false  result  given  by 
[CONTACT_132621] (when 
applicable);  
In order  to establish  the relatedness,  not all the criteria 
listed  above  might  be met at the same  time,  depending 
on the type of device/procedures and the serious  
event.  
Seriousness  
Serious Adverse Event (SAE) 
(ISO [ZIP_CODE]:2020  section  3.45)  An AE that:  
• Led to death  
• Led to a serious  deterioration  in the health  of the 
subject,  resultingin:  
o A life-threatening  illness  or injury,  or 
o A permanent  impairment  of a body 
structure or a body  function, or  
o In-patient  or prolonged  hospi[INVESTIGATOR_059],  or 
o Medical or surgical intervention to 
prevent  life-threateningillness  or injury 
or permanent impairment to a body 
structure or a body function,  
• Led to fetal  distress,  fetal  death  or a 
congenital abnormality orbirth defect.  
 
Note:  Planned  hospi[INVESTIGATOR_113617] a pre-existing 
condition, or a procedure required by [CONTACT_10396], 
without serious deterioration in health, is not 
considered a SAE.  
Serious  Adverse  Device  Effect  (SADE) 
(ISO [ZIP_CODE]:2020 section 3.44)  Adverse  device  effect  that has resulted  in any of 
the consequences characteristic of a serious 
adverse event.  
. 
Complication  An adverse  event  that includes  the following  is 
considered a complication:  
• Results  in death,  
• Involves  any termination  of significant 
device function, or  
• Requires  an invasive  intervention  
 
Non -invasive (21 CFR 812): when applied to a 
diagnostic  device  or procedure,  means  one that does 
not by [CONTACT_180996]:  
• Penetrate  or pi[INVESTIGATOR_600493],  the ocular  cavity, 
or the urethra, or  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 57 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 o Penetrate: to pass, extend, 
pi[INVESTIGATOR_835],  or diffuse  into or through 
something; to enter by 
[CONTACT_354028]; to gain 
entrance to  
o Pi[INVESTIGATOR_835]:  to force  a way into or through 
something  
• Enter  the ear beyond  the external  auditory 
canal, the nose beyond the nares, the 
mouth beyond the  pharynx, the anal canal 
beyond the rectum, or the vagina beyond 
the cervical os  
 
Note (FDA): Blood sampling that involves simple 
venipuncture  is considered  noninvasive,  and the use of 
surplus samples of body fluids or tissues that are left 
over from samples taken for non - investigational 
purposes is also considered noninvasive.  
Observation  Any Adverse  Event  that is not a complication.  
Note  1: Pulmonary  related  AEs will be the only  AEs 
requiring classification of either Complication or 
Observation by [CONTACT_600538].  
Unanticipated  Adverse  Device  Effect  (UADE)  
(21 CFR 812.3(s))  Any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or 
associated with, a device, if that effect, problem, or 
death, was not previously identified in a nature, 
severity, or degree of incidence in the investigational 
plan  or application  (including  a supplementary  plan  or 
application), or any other unanticipated serious 
problem associated with a device that relates to the  
rights,  safety,  or welfare  of subjects.  
Other  
Unavoidable  Adverse  Event  An Adverse  Event  inherent  to a surgical  procedure  that 
is expected to occur in all subjects for a projected 
duration according to the Investigator’s opi[INVESTIGATOR_1649],  
including,  but not limited  to: 
  
 
Event  Description  Timeframe 
(hours)  from 
the Surgical 
Procedure   
Pocket  site / Incisional  pain  72  
Mild  to moderate  bruising  / 
ecchymosis  [ADDRESS_795361]’s  participation,  starting  at the time  the informed  consent  form  is signed:  
• All Reveal  LINQTM Procedure  related  AEs 
• All Reveal  LINQTM System  related  AEs 
• All Serious  AEs 
• All Pulmonary  related  AEs 
• All Cardiovascular  related  AEs 
 
Reporting of AEs to Medtronic will occur on an Adverse Event e -CRF, including a description of the  
event, the diagnosis, the date of event onset, the date the site became aware of the event, the 
relatedness and seriousness of  the event, diagnostic tests and procedures performed, actions taken as  a 
result  of the event,  and outcome  of the event.  Each  AE must  be recorded  on a separate AE  eCRF. Subject 
deaths are also required to be reported and should be collected on an AE CRF with a Fatal outcome.  
Refer  to section  12.[ADDRESS_795362] definitions as outlined in Table  9. 
Upon receipt of AEs and DDs at Medtronic, a Medtronic representative will review the AE/DD for 
completeness  and accuracy  and when  necessary  will request  clarification  and/or  additional  information 
from  the investigator.  Medtronic  will utilize  the Medical  Dictionary  for Regulatory  Activities  (MedDRA), 
to assign a MedDRA term for each AE based on the information provided by [CONTACT_093].  
Regulatory  reporting  of AEs and DDs that could  have  led to a SADE  will be completed  according  to local 
regulatory requirements.  Refer to Table  [ADDRESS_795363] of required investigator and Medtronic reporting 
requirements and timeframes.  It is the responsibility of the investigator to abide by [CONTACT_600539]/EC responsible for oversight of the study at their site.  
For emergency contact [CONTACT_169280] a SAE and/or SADE, contact a Medtronic study representative 
immediately  (refer  to the study  contact  [CONTACT_600540]’s  study  documents  binder/investigator 
site file or refer to the Sponsor Contact [CONTACT_525978]).  
An Event  Adjudication  Committee  (EAC)  will review  the Pulmonary  related  AEs and will provide  a COPD 
event relatedness adjudication and a Complication or Observation classification for each Pulmonary  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 59 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 related  event.  The EAC will additionally  be providing  a death  classification  for all reported  AEs with  an 
outcome of fatal.  
Table  10: Adverse  Event  Classification  Responsibilities  
 
What  is classified?  Who classifies?  Classification  Parameters  
 
 
Relatedness  Investigator  Reveal  LINQ™ system  related,  Reveal  LINQTM procedure 
related,  Pulmonary Related,  Cardiovascular  related  
 
Sponsor  Reveal  LINQ™ system  related,  Reveal  LINQTM procedure 
related,  Pulmonary  Related,  Cardiovascular  related,  Heart 
Failure  Event,  COPD  event  
 
Seriousness  Investigator  SAE, Device  Deficiency  with SADE  potential  
Sponsor  SAE, Device  Deficiency  with SADE  potential,  UADE, 
Complication/Observation  
 
 
AE Term (Diagnosis)  Investigator  Based  on presenting  signs and symptoms  and other 
supporting  data 
Sponsor  MedDRA  term assigned  based  on the term provided  by 
[CONTACT_600541],  Non-sudden  Cardiac,  Non-Cardiac, 
Unknown  
 
 
12.5.2  Adverse Event and Device Deficiency Reporting Requirements 
Regulatory reporting of AEs and DDs will be completed according to local regulatory requirements. 
Investigator  and sponsor  reporting  requirements  are outlined  in Table  11. It is the responsibility  of the 
investigator  to abide  by [CONTACT_600542]’s IRB/EC.  
For adverse  events  and device  deficiencies  that require  immediate  reporting,  initial  reporting  may  be 
completed  by [CONTACT_600543]  (refer  to the study  contact  [CONTACT_600540]’s  study 
documents binder/investigator site file or refer to the contact [CONTACT_600544] 1 ). 
Table  11: Reporting  Requirements  
 
Serious  Adverse  Device  Effects  (SADEs)  
Investigator  submit  to: 
Medtronic  Submit  as soon as possible  as per local reporting  requirement,  but not later 
than within  [ADDRESS_795364] learns  of the event.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Regulatory  Authorities  Submit  per local reporting  requirement.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 60 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  as soon as possible  as per local reporting  requirement,  but not later 
than within  [ADDRESS_795365] learns  of the event.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Serious  Adverse  Events  (SAE)/  Adverse  Device  Effects  (ADE)  
Investigator  submit  to: 
Medtronic  Submit  as soon as possible  as per local reporting  requirement,  but not later 
than within  [ADDRESS_795366] learns  of the event.  
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
All other  AEs 
Investigator  submit  to: 
Medtronic  Submit  as soon as possible  as per local reporting  requirement  after the 
investigator  first learns  of the event.  
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Device  Deficiency  with SADE  potential  
Investigator  submit  to: 
Medtronic  Submit  as soon as possible  as per local reporting  requirement,  but not later 
than within  [ADDRESS_795367] learns  of the event.  
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
All other  Device  Deficiencies  
Investigator  submit  to: 
Medtronic  Submit  as soon as possible  as per local reporting  requirement,  but not later 
than within  [ADDRESS_795368] learns  of the event.  
Regulatory  Authorities  Submit  per local reporting  requirement.  
IRB/Ethics  Committee  Submit  per local reporting  requirement.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795369] be reported by [CONTACT_241756] (AE with fatal 
outcome)  as soon  as possible  after  the investigator  first learns  of the death.  In case  of death,  there 
should be one AE CRF with an outcome of fatal.  
In the event of a subject’s death, the inserted system should be explanted and returned to Medtronic 
for analysis whenever possible. Local laws and procedures must be followed where applicable. If any 
device  or system  component  is returned  to Medtronic,  internal  returned  product  reporting  systems  may 
be used to gather additional information about the returned device/component.  
A copy of the death certificate, if available and allowed by [CONTACT_54443]/local law, should be sent to the 
Medtronic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary report 
and all relevant hospi[INVESTIGATOR_600494], if available. If an 
autopsy is conducted, the autopsy report should also be sent to the Medtronic clinical study team if 
available and allowed by [CONTACT_54443]/local law. When the death occurs at a remote site, it is the investigati ve 
site’s  responsibility  to attempt  retrieval  of information  about  the death.  Additionally,  device  disposition 
information should be updated. In summary, the following data will be collected:  
• Date  of death  
• Detailed  description  of death  
• Cause  of death  
• Relatedness  to system  and/or  procedure  
• Device  interrogation  (if available,  postmortem  preferred)  
• Death  summary/hospi[INVESTIGATOR_20112]  (if available  and allowed  by [CONTACT_54443]/local  law) 
• Autopsy  report  (if available  and allowed  by [CONTACT_54443]/local  law) 
• Death  certificate  (if available  and/or  allowed  by [CONTACT_54443]/local  law) 
12.6.[ADDRESS_795370]’s  death. 
The Investigator shall classify each subject death per the following definitions:  
Cardiac  Death : A death  directly  related  to the electrical  or mechanical  dysfunction  of the heart.  
Sudden Cardiac Death (SCD) : Natural death due to cardiac causes, indicated by [CONTACT_54444]; preexisting heart disease may have 
been  known  to be present,  but the time  and mode  of death  are unexpected.  If time  of onset  cannot  be 
determined, SCD will alternatively be defined as any unexpected cardiac death occurring out of the 
hospi[INVESTIGATOR_54381].  
Non -sudden  Cardiac  Death : All cardiac  deaths  that are not classified  as sudden  deaths,  including  all 
cardiac deaths of hospi[INVESTIGATOR_54382].  
Non -cardiac  Death : A death  not classified  as a cardiac  death.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 62 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Unknown  Cardiac  Classification : Unknown  death  classification  is intended  for use only  when  there  is 
insufficient or inadequate information to classify the death.  
The EAC will review  all AEs with  a fatal  outcome  and provide  a final  adjudication  of both  COPD  event  and 
death classification. Regulatory reporting of subject deaths will be completed according to local 
regulatory requirements. Refer to Table [ADDRESS_795371] Complaint: Any written, electronic or oral communication that alleges deficiencies related to 
the identity,  quality,  durability,  reliability,  safety,  effectiveness  or performance  of a medical  device  that 
has been placed on the market.  
It is the responsibility of the investigator to report all product complaint(s) associated with a medical 
device  distributed  by [CONTACT_13735],  regardless  whether  they  are related  to intended  use, misuse  or abuse 
of the product.  Reporting  must be done immediately and via the regular channels for market -released 
products.  
Medtronic  will notify  the regulatory  authorities,  as applicable  for the following  incidents  immediately 
upon learning of them:  
• Any malfunction  or deterioration  in the characteristics  and/or  performance  of a device,  as well 
as any inadequacy in the labeling or instructions for use which led or might have led to the 
death or serious deterioration in the state of health of a patient, user, or other person.  
• Any technical  or medical  reason  resulting  in withdrawal  of a device  from  the market  by [CONTACT_13989].  
 
13. Data  Review  Committees   
13.1  Event  Adjudication  Committee  
At regular  intervals,  an Event  Adjudication  Committee  (EAC)  will review  and adjudicate  at a minimum,  all 
events  classified  by [CONTACT_600545]  a fatal  outcome. 
The EAC will provide  an adjudication  for COPD  event  and a Complication  or Observation  classification  for 
all AEs that are reviewed. The EAC will additionally provide a death classification for all AEs with an 
outcome  of fatal.  The EAC will consist  of a non-Medtronic  employed  physicians  that are not participating 
investigators for the study.  
Medtronic  personnel  may  facilitate  and participate  in an EAC meeting  but will be non-voting  members.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 63 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 For all adverse events reviewed by [CONTACT_131461], Medtronic will provide the EAC with the investigator’s 
description  and classification.  The EAC is responsible  for reviewing  the investigator’s  assessment  and 
supportive documentation (when available), reviewing applicable definitions, and determining final 
classifications for all adjudication parameters.  
13.[ADDRESS_795372]  to change  during  the clinical 
study. Periodic updates to CRO and core labs information will be sent to the centers as needed.  
Table  12: CRO Information  
 
Contact  [CONTACT_600546] X 
XXXXXXXXXX  
XXXXXXXXXXXXXXXXXXXXXXX  
XXXXXXXXXXXXXXXXXXXX  • Development  of study  electronic  case report  forms,  edit 
checks,  and study management reports.  
• Review  of electronic  case report  forms,  management  of 
discrepancies,  and coding of deviations.  
 
14. Statistical  Design  and Methods   
The LINQTM for COPD  is a prospective,  non-randomized,  multi -center,  observational,  pre-market  clinical 
study. The purpose of the study is to characterize the Reveal LINQ ™ derived data from patients with 
COPD.  
This is a feasibility  study  that is exploratory  in nature  and with  no hypothesis.  Therefore,  justification  on 
sample size is not required. The study plans to enroll up to [ADDRESS_795373] 12 months after the insertion of Reveal LINQ ™ device and download of either 
the LINQ HF or ALLEVIATE -HF investigational RAMware. The expected total study duration is 
approximately [ADDRESS_795374] follow -up with up to 1 mont h between enrollment and insertion.  
14.1  General  Aspects  of Analysis  
Medtronic  statisticians  or designees  will perform  all statistical  analyses.  
The study is exploratory in nature with no formal statistical hypothesis planned. A separate Statistical 
Analysis  Plan  (SAP)  will be developed  and include  a comprehensive description  of the statistical  methods 
and analyses  to be included  in the final study report.  Any change to  the data  analysis  methods described 
in the protocol will require an amendment only if it changes a principal feature of the protocol. Any 
other  change  to the data  analysis  methods  described  in the protocol,  and the justification  for making  the 
change, will be described in the clinical study report.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-[ADDRESS_795375]  exits  the study.  
14.3  Primary  Objective  
The primary objective is to characterize Reveal LINQ ™ derived data from patients with COPD by 
[CONTACT_600505] ™ derived  data  with  subsequent  COPD  events.  
14.3.[ADDRESS_795376] will be 
included in the analysis.  
 
According to section 5.1, COPD event is defined as an adverse event where the underlying COPD 
condition exacerbates beyond normal day -to-day variations, where an increase in dyspnea, cough, 
and/or  sputum  production  presents  with  acute  onset  and necessitates  supplementing  regular  COPD 
medications with antibiotics for respi[INVESTIGATOR_600479]/or steroids.  
14.3.3  Analysis  Methods  
Data  from  multiple  study  components  will be collected  in this study,  of which  the Reveal  LINQ ™ HF 
derived data is of the most interest. This includes subcutaneous electrocardiogram, impedance, 
temperature, accelerometer and patient activity measurements.  
Descriptive statistics such as mean and standard deviation for continuous variables and count and 
proportion for categorical variables will be used to summarize the derived data from Reveal LINQ ™ HF. 
The relationship between changes in LINQ ™ derived data and COPD events per EAC adjudication will be 
evaluated. Specifically, for each subject that has experienced at least one COPD event per EAC 
adjudication,  the average  daily  measurements  of LINQ ™ derived  data  before  and after  a COPD  event  will 
be plotted to i dentify patterns and signals related to the occurrence of the COPD event.  
Baseline data such as demographics, medical  history, physical exam (heart rate, blood pressure, weight, 
spi[INVESTIGATOR_105186],  etc.),  and blood  measurements  (Creatinine,  BNP,  NT-pro BNP,  White  Blood  Cells 
and Eosinophils) will also be summarized using descriptive statistics.  
14.3.4  Determination  of Subjects/Data  for Analysis  
Enrolled subjects who have Reveal LINQTM device successfully inserted and have  either the LINQ ™ HF or 
ALLEVIATE -HF investigational  RAMware  successfully  downloaded  to the device  and who  have  completed 
a first successful CareLink transmission.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 65 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 14.4  Sample  Size Determination  
There  are no sample  size requirements  as this is an observational  study  with  no hypothesis  for the study 
objective. A sample size of up to 100 enrolled subjects was selected assuming sufficient data can be 
collected from this cohort to explore the relationship between changes in LINQ ™ derived data with 
COPD events.  
According  to a review  by [CONTACT_600547]., the annual  rates  of COPD  exacerbations  were  estimated  to be 
as low as 0.[ADDRESS_795377] 120 COPD exacerbations.  
Assuming  50%  of the COPD  exacerbations  would  meet  the study  definition  of “COPD  event”,  a total  of 
60 COPD  events  would  be expected.  
14.5  Minimization  of Bias 
Selection  of subjects,  treatment  of subjects,  and evaluation  of study  data  are potential  sources  of bias. 
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Subjects  will undergo  screening  to confirm  eligibility  with  defined  inclusion/exclusion  criteria  prior 
to enrollment.  
• All sites  will use the same  version  of the Clinical  Investigation  Plan  and electronic  case  report  forms 
(eCRFs).  
• All investigational  site personnel  and Medtronic  personnel  will be trained  using  standardized 
training materials.  
• Monitoring  visits  will be conducted  for adherence  to the CIP and verification  of source  data.  
• An independent  Event  Adjudication  Committee  (EAC)  will be used  to review  and adjudicate  at a 
minimum, all Pulmonary related AEs and all AEs with a fatal outcome.  
• A statistical  analysis  plan  will be developed  prior  to analyzing  data.  The plan  will document  all pre- 
specified analyses and analysis methods.  
In summary,  potential  sources  of bias that may  be encountered  in this clinical  study  have  been 
considered and minimized by [CONTACT_54415].  
14.6  Missing  data 
Missing  data  will not be imputed.  An adjudicated  COPD  event  will be considered  in the analysis  to assess 
changes in LINQ ™ derived data if it has Reveal LINQ ™ data before and after the event onset date.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 66 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 14.7  Additional  Considerations  Due to COVID -19 
• Subject  follow -up visits.  
Follow -up visits  every  three  months  post  device  insertion  will be done  by [CONTACT_420600]-person 
if desired. The flexibility in the way to complete these visits will allow subjects to continue to be 
followed in the study as well as to follow local COVID -19 guidelines.  
• COPD  exacerbation  rate.  
A patient  with  COVID -[ADDRESS_795378] of COVID -19 on the COPD exacerbation rate is unknown.  
• COPD  event  outcome.  
Under potentially limited care resources of sites due to COVID -19, subjects with COPD may 
experience  delayed  treatment  that could  also increase  the subject’s  risk of worse  outcomes.  In 
addition,  subjects  with  COPD  may  experience  worse/poorer  event  outcomes  if also infected  by 
[CONTACT_4113] -19. 
 
15. Ethics   
15.1  Statement(s)  of Compliance  
The LINQTM for COPD Study will be conducted according to the Declaration of Helsinki, Version 2013, 
Clinical Investigation  Plan,  Good  Clinical  Practice (GCP) and  in accordance  to the national and  local laws, 
regulations,  standards,  and requirements  of the countries/geographies  in which  the study is  conducted. 
The principles of the Declaration of Helsinki are implemented in this study by [CONTACT_600548], Ethics Board approval, study training, clinical trial registration, and risk benefit 
assessment.  The sponsor  shall  avoid  improper  influence  on, or inducement  to, the subject,  monitor,  any 
investigator(s) or other parties participating in, or contributing to, the LINQTM for COPD Study.  
This study will be conducted in compliance with international ethical and scientific quality standards, 
known  as good  clinical  practice  (GCP).  GCP includes  review  and approval  by [CONTACT_600549] a study, continuing review of an ongoing study by [CONTACT_600550] a subject before initiating the study.  
Ultimately,  all sites  in all geographies  will follow  and comply  with:  
• Principles  of Declaration  of Helsinki  
• 21 CFR Part 11: Electronic  Records,  Electronic  Signatures  
• 21 CFR Part 54: Financial  Disclosure  by [CONTACT_168714]  
• The Clinical  Trial  Agreement  
• The procedures  described  within  this CIP 
• Local  Ethics  Board  Requirements  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 67 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 
In addition to the regulatory requirements outlined above, the study will be conducted according to 
federal,  national  and local  laws,  regulations,  standards,  and requirements  of the countries/geographies 
where the study is being conducted. These include but are not limited to the following:  
In the US, the study  will be conducted  in compliance  with:  
• 21 CFR Part 50: Protection  of Human  Subjects  
• 21 CFR Part 56: Institutional  Review  Boards  
• 21 CFR Part 803:  Medical  Device  Reporting  
• 21 CFR Part 54: Financial  Disclosure  
• 21 CFR Part 812 Investigational  Device  Exemptions  
 
The study  will not begin  until  IRB/EC  and regulatory  authority  approvals/notification,  as appropriate,  are 
received.  
The study will be publicly registered on http://clinicaltrials.gov  prior to first enrollment in accordance 
with  the [ADDRESS_795379] (FDAAA)  and Declaration  of Helsinki  on 
(PL 110 -85, Section 810(a)).  
 
16. Study  Administration   
16.[ADDRESS_795380] therefore 
be allowed access to the subjects’ case histories (clinic and hospi[INVESTIGATOR_1097], and other source 
data/documentation) upon request as per the informed consent form, Data Protection Authorization 
(where applicable) and  clinical trial agreement.  The principal investigator [INVESTIGATOR_600495].  
16.1.1  Monitoring  Visits  
Monitoring  for the study,  including  site initiation  visits,  interim  monitoring  visits,  and closeout  visits,  will 
be done in accordance to the study -specific monitoring plan.  
Monitoring visits may be conducted periodically to assess site study progress, the investigator’s 
adherence to the CIP, and regulatory compliance, including but not limited to IRB/EC approval and 
review of the study, maintenance of records and reports, and  review of source documents against 
subject  eCRFs.  Monitors  review  site regulatory  and study  compliance  by [CONTACT_600551]- 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 68 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 compliance  and communicating  those  findings  to site personnel.  Monitors  may  work  with  study 
personnel to determine recommendations for preventative/corrective/effectiveness action(s) 
recommendations and to identify trends within the study or at a particular site.  
Frequency of monitoring visits may be based upon subject enrollment, duration of the study, study 
compliance,  number  of adverse  events,  number  of deviations,  findings  from  previous  monitoring  visits 
and any suspected inconsistency in data that requires investigation.  Regulatory documents may be 
reviewed at each study center.  
16.2  Data  Management  
Electronic  case  report  form  (e-CRF)  data  will be stored  in a secure,  password -protected  database  which 
will be backed up nightly.  Data will be reviewed using programmed and manual data checks.  Data 
queries will be  made available to  sites for resolution.  Study management reports  may be generated  to 
monitor data quality and study progress.  
Device  data  from  CareLink  transmissions  will be uploaded  to secure  servers.  Upon  receipt,  device  data 
will be maintained within databases and retrieved for analysis and reporting.  
Changes to the data elements in the electronic system will retain the original data and an audit trail 
(date,  time,  and originator  of the change  and reason).  It is possible  that AE and device  data  files may  be 
provided  to Medtronic before the PI [INVESTIGATOR_600496] e -CRF.  At the end  of the study, the 
data will be frozen and will be retained indefinitely by [CONTACT_13735].  
16.[ADDRESS_795381]  Access  to Source  Data/Documents  
The sponsor  or a regulatory  authority,  including  the FDA,  may  audit  or inspect  the study  site to evaluate 
the conduct  of the study.  The clinical  investigator(s)/institutions(s)  shall  allow  study related  monitoring, 
audits, Ethics Board review and regulatory inspection by [CONTACT_169293]/documents.  
16.[ADDRESS_795382] party designated by 
[CONTACT_600552] a key coded  form,  unless  it’s impossible  to make  it anonymous,  for instance,  where  the 
patient’s name [CONTACT_131514], such as fluoroscopy images.  
16.[ADDRESS_795383]. 
Insurance information for participating geographies is provided below.  
Medtronic  maintains  appropriate clinical  study liability  insurance coverage  as required  under  applicable 
laws  and regulations  and will comply  with  applicable  local  law and custom  concerning  specific  insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB/EC.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 69 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 16.6  CIP Amendments  
Approval  of the CIP is required  from  the following  groups  prior  to any study  procedures  at a study 
center:  
• Medtronic  
• An independent  Institutional  Review  Board  / Ethics  Committee  
Similarly,  approval  of subsequent  revisions  to the CIP from  the above -mentioned  groups  is required  at 
each study center prior to implementation of the revised CIP at that center.  
16.[ADDRESS_795384]  Retention  
16.7.1  Investigator  Records  
The investigator  is responsible  for the preparation  and retention  of the records  including,  but not limited 
to those cited below. All of the below records, with the exception of case history records and case  
report  forms  (CRFs),  should  be kept in  the Investigator  Site File (i.e.,  the study  binder  provided  to the 
investigator) or Subject Study Binder. CRFs must be maintained and signed electronically within the 
electronic data capture system during the study. The  following records are subject to inspection and 
must  be retained  for a period  of two years  (or longer  as local  law or hospi[INVESTIGATOR_239005]) 
after the date on which the investigation is terminated. Measures shall be taken to avoid loss or 
premature destruction.  
• All correspondence  between  the IRB, sponsor,  monitor,  regulatory  authority  and/or  the 
investigator that pertains to the investigation, including required reports  
• Subject’s  case  history  records,  including:  
o Signed  and dated  informed  consent  form  
o Observations  of adverse  events/adverse  device  effects/device  deficiencies  
o Medical  history  
o Baseline,  LINQ ™ Insertion  and follow -up data  (if applicable)  
o Documentation  of the dates  and rationale  for any deviation  from  the protocol  
• List of investigation  sites  
• Insurance  certificates  (if applicable)  
• All approved  versions  of the CIP and Informed  Consent  Form  
• Fully  executed  Clinical  Trial  Agreement  
• Curriculum  Vitae  of principal  investigator  [INVESTIGATOR_9627]-investigators/sub -investigators  
• Documentation  of delegated  tasks  
• Study  training  records  for site personnel  involved  in the study  
• IRB approval  documentation,  including  the IRB composition  where  required  by [CONTACT_2371], and written 
information that the investigator or other study staff, when member of the IRB, did not 
participate in the approval process  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 70 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Regulatory  authority  correspondence,  notification  and approval,  where  required  by [CONTACT_169294]  
• Any other  records  that local  regulatory  agencies  require  to be maintained  
• Final  Study  Report  including  the statistical  analysis  
16.7.2  Sponsor  Records  
Medtronic  shall  maintain  the following  accurate,  complete,  and current  records  which  include,  but are 
not limited to:  
• All correspondence  which  pertains  to the investigation  
• Executed  Clinical  Trial  Agreement  for all participating  sites  
• Curriculum  vitae  (signed  and dated  as required  by [CONTACT_169291])  of principal  investigator  [INVESTIGATOR_9627]- 
investigators/sub -investigators at participating sites  
• Documentation  of delegated  tasks  for all participating  sites  
• Study  training  records  for site personnel  and Medtronic  personnel  involved  in the study  
• All approved  informed  consent  versions,  and other  information  provided  to the subjects  and 
advertisements, including translations  
• Copi[INVESTIGATOR_600497]/roster/letter of assurance, if applicable  
• Electronically  signed  and dated  eCRFs  
• List of names,  addresses,  telephone  numbers  and professional  position  of the clinical 
investigators and coordinating clinical investigator(s), if appointed  
• Names  and addresses  of the institutions  in which  the clinical  study  will be conducted  
• Regulatory  authority  correspondence,  notification  and approval  as required  by [CONTACT_169294]  
• Names/contact  [CONTACT_239089]  
• Monitoring  reports  
• Site qualification  visit reports  
• Statistical  analyses  and underlying  supporting  data  
• Final  report  of the clinical  study  
• The Clinical  Investigation  Plan  and study  related  reports,  and revisions  
• Sample  of CRFs  
• Any other  records  that local  regulatory  agencies  require  to be maintained  
16.8  Reporting  Requirements  
16.8.1  Investigator  Reports  
The investigator  is responsible  for the preparation  (review  and signature)  and submission  to the 
sponsor  of all case report  forms,  adverse  events  and adverse  device  effects  (reported  per the 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 71 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 country -specific  collection  requirements),  device  deficiencies,  deaths,  and any deviations  from the 
Clinical  Investigation  Plan. If any action  is taken  by [CONTACT_2717]/EC  with respect  to this clinical  study, 
copi[INVESTIGATOR_600498] a timely  manner.  Reports 
are subject  to inspection  and to the retention  requirements  as described  above  for investigator 
records.  Safety  data investigator  reporting  requirements  are listed in section  12.5.2.  The 
investigator  shall prepare  and submit  in a complete,  accurate  and timely  manner  the reports  listed 
in this section.  
Table  13: Investigator  Reports  
 
Report  Submit  to Description/Constraints  
Withdrawal  of IRB 
Approval  (either 
suspension  or 
termination)  Sponsor  and 
Relevant 
Authorities,  if 
applicable  The investigator  must report  a withdrawal  of approval 
by [CONTACT_600553]’s  part of the 
investigation  within  5 working  days.  
 
 
 
 
Study  Deviations   
 
 
Sponsor  and 
IRB/EC  Notice  of deviations  from the CIP to protect  the life or 
physical  wellbeing  of a subject  in an emergency  shall be 
given  as soon as possible,  but no later than [ADDRESS_795385] comply with IRB/EC 
policies and/or  local laws and/or  regulatory agency 
requirements and must be reported to Medtronic as 
soon as possible upon  the center  becoming  aware of 
the deviation.  
 
 
Progress  Report  Sponsor  and 
IRB/EC  and 
relevant 
authorities  if 
applicable   
The investigator must submit this report to the 
sponsor  and IRB at regular  intervals,  but in no event 
less than yearly.  
 
 
Final Report  Sponsor  and 
IRB/EC  and 
relevant 
authorities  if 
applicable   
This report must be submitted within 3  months of 
study  completion  or termination  of the investigation  or 
the investigator’s part of  the investigation.  
16.8.2  Sponsor  Reports  
Required  sponsor  reports  are listed in Table  14 below.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 72 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 Table  14: Sponsor  Reports  
 
Report  Submit  to Description/Constraints  
 
Premature 
Termination  or 
Suspension  of the 
Clinical  Investigation  Investigators, 
IRBs/ECs, 
regulatory 
authorities  (if 
required  per local 
regulations)  Provide  prompt  notification  of termination  or suspension  and 
reason(s).  
Progress  Reports  IRB Progress  reports  will be submitted  at least annually.  (21 CFR 
812.150(b)(5),  812.36(f)  
Recall  and device 
disposition  Investigators, 
IRB Notification  within  [ADDRESS_795386]  that an investigator  return,  repair,  or 
otherwise  dispose  of any devices.  (21 CFR 812.150(b)(6))  
 
 
Study  Deviations   
 
Investigators  Ensure  that all deviations  from the Clinical  Investigation  Plan 
are reported  on the case report  forms  and the final report  of 
the clinical  investigation . 
 
Site specific  study  deviations  will be submitted  to 
investigators  annually.  
 
 
Final Report  Investigators, 
IRB/EC,  
regulatory 
authorities  (if 
required  per local 
regulations)  Sponsor  final report  including  study analyses  will be provided.  
Significant  risk device 
determination  FDA If an IRB determines  that the device  is a significant  risk 
device,  the sponsor  shall submit  to FDA a report  of the IRB’s 
determination  within  5 working  days after sponsor  learns  of 
the determination.  (21CFR  812.150(b)(9))  
Medtronic  records  and reports  will be stored  in a password -protected  document  management  system.  
The sponsor  and principal  investigator  [INVESTIGATOR_600499](s). They shall take measures to prevent accidental or premature 
destruction of these documents. The principal investigator [INVESTIGATOR_600500]/party and document the transfer  at the investigation site or at the sponsor's facility.  
16.9  Publication  and Use of Information  
Publications  from  the LINQ ™ for COPD  Study  will be handled  according  to Medtronic’s  Policies  and 
Standard Operating Procedures and as indicated in the Clinical Trial Agreement.  
16.9.1  Publication  Committee  
The LINQ ™ for COPD  Study  will utilize  a Publication  Committee  which  will include  the study  Oversight 
Committee member as well as Medtronic personnel.  This committee will  manage study publications 
with the goal of publishing findings from the data.  
The Publication  Committee’s  role is to: 
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 73 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Manage  elements  addressed  in the publication  plan  as outlined  in this section  
• Develop  the final  Publication  Plan  under  a separate  cover  
• Execute  the Publication  Plan 
• Oversee  the publication  of primary,  secondary  and ancillary  study  results  
• Review  and prioritize  publication  proposals  
• Provide  input  on publication  content,  and 
• Apply  and reinforce  the authorship  guidelines  set forth  in the Publication  Plan.  
Membership  in the Publication  Committee  does  not guarantee  authorship.  The committee  will meet  as 
needed.  
16.9.2  Management  of Primary,  and Ancillary Publications  
The Publication Committee reviews, prioritizes, and manages all publications including primary and 
ancillary publications.  Primary publications are those that address analyses of the primary objective as 
specified in the Clinical Investigation Plan. An ancillary publication is any publication that does not 
address the primary study objective identified in the Clinical Investig ation Plan.  They include 
publications proposed and developed by [CONTACT_600554], other Medtronic departments or 
entities,  clinicians  participating  in this clinical  study,  and clinicians  not participating  in this clinical  study. 
The committee will work with Medtronic to ensure that requests do not present conflicts with the 
primary results, other proposals, are not duplicative, and to determine which ancillary publication 
proposals, if any, will be supported.  
The committee  may  decide  that no publications,  including  abstracts,  will be published  prior  to the end of 
the study or with individual site data.  Requests for publications on study objectives utilizing subset data 
(e.g., regional) will be evaluated for scientific validity and the ability of Medtronic to provide resources.  
16.9.3  Criteria  for Determining  Authorship  
Publications  will adhere to  authorship  criteria defined  by [CONTACT_600555] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, 
www.icmje.org).  Individual  authorship  criteria  defined  by [CONTACT_600556].  
Decisions regarding authorship and contributor ship will be made by [CONTACT_600554]. The 
selected  authors  will be responsible  for drafting  the publication.  All selected  authors  must  fulfill  ICMJE 
authorship conditions to be listed as authors.  
All investigators  not listed  as co-authors  will be acknowledged  as the “Medtronic  LINQ ™ for COPD  Study 
Investigators” and will be individually listed according to the guidelines of the applicable scientific 
journal when possible. Any other contributors will be acknowledged by [CONTACT_54464].  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 74 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 16.9.4  Transparency  
Transparency  of study  results  will be maintained  by [CONTACT_354062]:  
• A final report describing the results of all objectives and analysis will be distributed to all 
investigators  and IRBs/ECs  and Competent  Authorities  of participating  countries  when  required 
by [CONTACT_1769]  
• Registering  and posting  the study  results  on ClinicalTrials.gov  based  on the posting  rules 
stipulated  
• Submitting  for publication  the primary  study  results  after  the study  ends  
• Disclosing  conflicts  of interest  (e.g.,  financial)  of the co-authors  of publications  according  to the 
policies set forth by [CONTACT_54466]  
• Making  an individual  site’s  study  data  accessible  to the corresponding  investigator  after  the 
completion of the study, if requested  
16.10  Suspension  or Early  Termination  
16.10.1  Planned  Study  Closure  
Study  Closure  is a process  initiated  by [CONTACT_239101] a study  closure  letter.  Study  closure  is defined  as 
closure of a clinical study that occurs when Medtronic and/or regulatory requirements have been 
satisfied  per the CIP and/or  by a decision  by [CONTACT_600557],  whichever  occurs  first. 
The study closure process is complete upon distribution of the Final Report or after final payments, 
whichever occurs last.  Ongoing IRB/EC oversight is required until the overall study closure process is 
complete. Upon study closure, subjects should be managed and followed per physician discretion.  
16.10.[ADDRESS_795387].  This is possible for the whole study or a single  
site.  In the event the whole study or a single site is terminated, subjects will be exited.  
[IP_ADDRESS]  Study -wide  termination  or suspension  
Possible  reasons  for considering  study  suspension  or termination  of the study  include  but are not limited 
to: 
• Adverse  events  associated  with  the system  or product  under  investigation  which  might  endanger 
the safety or welfare of the subject  
• Observed/suspected  performance  different  from  the product’s  design  intent  
• Decision  by [CONTACT_600558]  (where  the study  is operating  under  regulatory  body 
authority)  
• Technical  issues  during  the manufacturing  process  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 75 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 [IP_ADDRESS]  Investigator/study  site termination  or suspension  
Possible  reasons  for clinical  investigator  or site termination  or suspension  include  but are not limited  to: 
• Failure  to obtain  initial  IRB/EC  approval  or annual  renewal  of the study  
• Persistent  non-compliance  to the clinical  investigation  (e.g.  failure  to adhere  to inclusion/exclusion 
criteria, failure to follow subjects per scheduled follow -ups)  
• Lack  of enrollment  
• Noncompliance  to regulations  and the terms  of the CTA (e.g.  failure  to submit  data  in a timely 
manner,  failure  to follow -up on data  queries  and monitoring  findings  in a timely  manner,  etc.)  
• Institutional  Review  Board/Ethics  Committee  suspension  of the site 
• Fraud  or fraudulent  misconduct  is discovered  (as defined  by [CONTACT_600559])  
• Investigator  request  (e.g.  no longer  able  to support  the study)  
16.10.3  Procedures  for Termination  or Suspension  
[IP_ADDRESS]  Medtronic -initiated  and regulatory  authority -initiated  
• Medtronic  will promptly  inform  the clinical  investigators  of the (early)  termination  or suspension 
and the reasons and inform the regulatory authority(s) where required  
• In the case  of study  termination  or suspension  for reasons  other  than  a temporary  IRB/EC  approval 
lapse, the investigator will promptly inform the IRB/EC  
• In the case  of study  termination,  the investigator  must  inform  the subjects  and may  inform  the 
personal physician of the subjects to ensure appropriate care and follow -up is provided  
• In the case  of a study  suspension,  subject  enrollment  must  stop  until  the suspension  is lifted  by 
[CONTACT_13735]  
• In the case  of a study  suspension,  enrolled  subjects  should  continue  to be followed  out of 
consideration of their safety, rights and welfare  
[IP_ADDRESS]  Investigator -initiated  
• The investigator  will inform  Medtronic  and provide  a detailed  written  explanation  of the termination 
or suspension  
• The investigator  will promptly  inform  the institution  (where  required  per regulatory  requirements)  
• The investigator  will promptly  inform  the IRB/EC  
• The investigator  will promptly  inform  the regulatory  authorities  (if required)  
• The investigator  will promptly  inform  the subjects  and/or  the personal  physician  of the subjects  to 
ensure appropriate care and follow -up is provided  
• In the case  of a study  suspension,  subjects  enrolled  should  continue  to be followed  out of 
consideration of their safety, rights and welfare  
[IP_ADDRESS]  Ethics  Committee -initiated  
• The investigator  will inform  Medtronic  and provide  a detailed  written  explanation  of the termination 
or suspension within 5 business days  
• The investigator  will promptly  inform  the regulatory  authorities  (if required)  
• Subject  enrollment  must  stop  until  the suspension  is lifted  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 76 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 • Subjects  already  enrolled  should  continue  to be followed  in accordance  with  IRB/EC  policy  or its 
determination that an overriding safety concern or ethical issue is involved  
• The investigator  will inform  his/her  institution  (where  required  per local  requirements)  
• The investigator  will promptly  inform  the subjects,  and/or  the personal  physician  of the subjects, 
with the rationale for the study termination or suspension  
 
17. References   
 
1. Rabe  K, Watz  H, Chronic  Obstructive  Pulmonary  Disease.  The Lancet,  Vol 389,  Issue  [ZIP_CODE],  May  [ADDRESS_795388];21(7):[ADDRESS_795389],  Louise  B. Murphy,  Olga  Khavjou,  Wayne  H. Giles,  James  B. Holt,  and Janet  B. Croft.,  Total  and 
state -specific medical and absenteeism costs of COPD among adults aged ≥ [ADDRESS_795390], 147 (1), pp. 31 -45 (January 2015)  
4. Abraham,  William,  et. al. Intrathoracic  Impedance  vs Daily  Weight  Monitoring  for Predicting 
Worsening Heart Failure Events: Results of the Fluid Accumulation Status Trial (FAST). 
Congestive Heart Failure, Vol 17, Issue 2, March/April 2011.  
5. Adamson,  et. al. Continuous  Autonomic  Assessment  in patients  with  symptomatic  heart  failure: 
Prognostic Value of Heart Rate variability measured by [CONTACT_600560], Circulation 110:2389 -2394, 2004.  
6. Goetze, Stephan, et. al. Ambulatory respi[INVESTIGATOR_600501]:  a novel  ambulatory  parameter  to optimize  heart  failure  management.  J Inter  Card 
Electrophysiol, 43:21 -29, 2015.  
7. Katra, Rodolphe, Niranjan Chakravarthy, Remote At -Home Detection and Monitoring of 
Functional  Chronotropic  Incompetence  in Heart  Failure  Patients.  J of Cardiovasc  Trans.  Res. 
4:14 -20, 2011.  
8. Yu CM, Wang  L, Chau  E, et al. Intrathoracic  impedance  monitoring  in patients  with  heart  failure: 
correlation with fluid status and feasibility of early warning preceding hospi[INVESTIGATOR_059]. 
Circulation 2005;112(6):841 -8. 
9. Roy-Chaudhury, P, Williamson, DE, Tumlin, JA, Kher, VK, Prakash, K, Charytan DM, Tiwari, SC, 
Pokhariyal, S, Podoll, AS. “Monitoring in Dialysis (MiD) Study: Exploring the Timeline and 
Etiology  of Increased  Arrhythmias  in Hemodialysis  (HD)  Patients.”  J Am Soc Nephrol;  2015:  Late 
Breaking Clinical Trial Poster (SA -PO1112).  
10. Ekman,  I., et. al. Symptoms  in patients  with  heart  failure  are prognostic  predictors:  insights  from 
COMET. Journal of Cardiac Failure. 11, 288 –292, 2005.  
11. Silva,  L., et. al. Persistent  orthopnea  and the prognosis  of patients  in the heart  failure  clinic. 
Congestive Heart Failure, 10, 177 –180, 2004.  
12. Pürerfellner H, Sanders P, Pokushalov  E, Di Bacco M, Bergemann T, Dekker LR.  Miniaturized 
Reveal  LINQ  insertable  cardiac  monitoring  system:  First -in-human  experience.  Heart  Rhythm. 
2015 Jun;12(6):1113 -9. 
13. Seemungal  et. Al. Exacerbation  rate,  health  status  and mortality  in COPD  – a review  of potential 
interventions, International Journal of COPD, 2009.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 77 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 18. Appendices   
18.1  Informed  Consent  Template(s)  
Patient  informed  consent  form templates  will be provided  under  separate  cover.  
18.2  Data  Collection  Elements  (Electronic  Case  Report  Forms)  
Electronic  Case Report  Forms  for the LINQTM for COPD  study  will be provided  under  separate 
cover.  Final eCRFs  will be provided  to sites via the electronic  data management  system  after the 
site has fulfilled  all requirements  for database  access.  
18.3  LINQTM for COPD  Study  Procedure  Handbook  
A LINQ™ for COPD  Study  Procedure  handbook  that will provide  instructions  on the following:  how 
to apply and utilize  the DR220  Holter  during  the Spi[INVESTIGATOR_487383], EMFIT  Bed Monitor  instructions, 
and Subject  diary instructions  will be provided  under  a separate  cover.  
18.[ADDRESS_795391] of participating  investigators  and institutions  (including  names,  titles/professional 
positions,  address(es),  and telephone  numbers)  where  study  activities  will be conducted  will be 
distributed  under  a separate  cover  when  available.  Approval  of the LINQTM for COPD  Study  CIP will 
be documented  by [CONTACT_600561] a separate  investigator  agreement.  
18.[ADDRESS_795392] of participating  IRBs and the Chairperson(s)  will be provided  under  separate  cover. 
This information  will be updated  throughout  the course  of the study.  The updated  list will be 
maintained  at Medtronic  and will be available  upon request.  
18.6  Committees  
The Reveal  LINQ™ for COPD  study  will utilize  an Event  Adjudication  Committee  (EAC)  for the 
assessment  of Pulmonary  related  AEs and AEs with a fatal outcome.  
The Reveal  LINQ™ for COPD  study  may utilize  a Publication  Committee  aiming  to manage  study 
publications.  
A Data Monitoring  Committee  (DMC)  is not needed  for this study.  This decision  was made  based 
on the following  criteria:  it is felt there are no additional  benefits  of a DMC reviewing  the data in 
addition to the  Event Adjudication Committee (EAC)  
The updated  member  lists will be maintained  at Medtronic  and will be made  available  upon request.  
18.7  Labeling  
Labeling  for the investigational  RAMware  will be provided  under  separate  cover.  Labeling  for all 
system  components  used in this study  can be found  with each package  insert  and/or  will be 
available  on http://manuals.medtronic.com.  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 78 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
 19. Version  History   
 
Version  Summary  of Changes  Author(s)/Title  
 
1.0  
• Not Applicable,  New  Document  XXXXXXXX , Clinical  Research 
Specialist  
XXXXXXXX , Sr. Principal 
Statistician  
 
 
 
2.0 • Updated  exclusion  criteria  
• Inserted  a max  number  of subjects  per site that 
can utilize the EMFIT bed monitor  
• Clarified  manual  transmission  requirements  
• Made  minor  formatting  and grammar  changes  
• Updated  CIP title to Reveal  LINQTM for COPD 
Study   
 
XXXXXXXX , Clinical  Research 
Specialist  
 
 
3.0 • Removed  “electronic”  when  referencing  to the 
subject diary  
• Added  clarification  regarding  potential  risks  in 
section 10.1  
• Adjusted  required  manual  transmissions  to a bi- 
weekly basis   
 
XXXXXXXX , Clinical  Research 
Specialist  
 
 
 
 
 
 
 
 
 
4.0 • Updated  I/E criteria  
• Added  option  of investigational  ALLEVIATE -HF 
Software and RAMware  
• 6-month in office visit changes: Made the visit to 
be optional and allowed it to be done in -office at 
any time  during  study  participation,  except  within 
[ADDRESS_795393] X -ray procedure  
• Allowed  for prior  spi[INVESTIGATOR_600502] 6 months  
• Changed  diary  requirement  to be weekly  and 
when symptoms change  
• Changed laboratory collection requirement to 
either Brain natriuretic peptide (BNP) OR N - 
terminal  brain  natriuretic  peptide  (NT-proBNP) 
instead of requiring both   
 
 
 
 
 
 
XXXXXXXX  Clinical  Research 
Specialist  
 
XXXXXXXXXXXXXXX , Principal 
Statistician  
5.0 • The CIP was transitioned  to CIP template  version  
E from  version  3. XXXXXXXXXXXXXXXX , Clinical 
Research Specialist  
Reveal  LINQTM for COPD  Study  Clinical  Investigation 
Plan 
Version  5.0, 
1-DEC-22 Page 79 of 79 
Medtronic  Business  Restricted  
CONFIDENTIAL  056-F275 Rev E Clinical  Investigation  Plan Template   
  
 • Updated  the follow -up period  to [ADDRESS_795394] patient  enrolled and the expected  total study 
duration to 33 months in section 4 (synopsis), 
section 7 (study design) and section 7.1 
(duration).  
• Updated  figure  1 (study  flowchart)  to correspond 
to the follow -up period of 6 months.  
• Footer was added in section 3. Synopsis and 
section  9.[ADDRESS_795395]-2021.  
• Sections  (7.[ADDRESS_795396] Accountability, 8.1 Investigator/ 
Investigation Site Selection, 8.[ADDRESS_795397]  and 10.23.6 
Conditional  Disengagement)  were  updated.  
• Scheduled  follow  up visits  was updated  in section 
10.12  
• Definition  for Serious Health  Threat  (Section  12.4 
Definitions/Classifications  (table  9)) was removed 
as this definition was incorrectly included in the 
CIP and it  is not necessary as this study is not ISO  
compliant.   
 